Description: These two income stocks can weather every cycle.

Description: Johnson & Johnson (NYSE:JNJ), a worldwide leader in multiple myeloma therapies, today announced positive topline results from the investigational Phase 3 MajesTEC-9 study of TECVAYLI® (teclistamab-cqyv) monotherapy, showing a 71% reduction in the risk of disease progression or death and a 40% reduction in the risk of death in a patient population that was predominantly refractory to anti-CD38 therapy and lenalidomide. Data confirm superior progression-free survival (PFS) and overall survival (OS

Description: BMY reports positive late-stage data for Camzyos in adolescents with oHCM, expanding its cardiovascular outlook amid pipeline setbacks and rising competition.

Description: Johnson & Johnson (JNJ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Description: Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Description: (Updates with Johnson & Johnson's response in the fourth paragraph.) Johnson & Johnson (JNJ) co

Description: Health care stocks were lower late Tuesday afternoon, with the NYSE Health Care Index down 0.5% and

Description: Health care stocks were lower Tuesday afternoon, with the NYSE Health Care Index down 0.6% and the S

Description: The total market size of systemic lupus erythematosus is expected to increase in the 7MM during the forecast period, driven by ongoing clinical research of therapies such as nipocalimab (Johnson & Johnson), Litifilimab (Biogen and Royalty Pharma), Ianalumab (Novartis), Cenerimod (Idorsia and Viatris), Rapcabtagene autoleucel (YTB323) (Novartis), KK-4277 (Kyowa Kirin), and others, and better diagnostic tools, which might improve the prognosis of the disease.New York, USA, Jan. 13, 2026 (GLOBE NEW

Description: Tremfya and Icotide are touted as key growth drivers in J&J’s strongly performing innovative medicines business.

Description: Key market opportunities in the Bipolar Disorder market include developing targeted treatments for bipolar depression due to current unmet needs, capitalizing on late-stage pipeline products projected to influence market growth, and leveraging strategic partnerships and emerging players with strong portfolios.Dublin, Jan. 13, 2026 (GLOBE NEWSWIRE) -- The "Bipolar Disorder: Opportunity Assessment and Forecast" report has been added to ResearchAndMarkets.com's offering.This report covers the 7MM a

Description: Oncology is set to play a major role in J&J’s revenue outlook, generating $50bn in sales in 2030.

Description: Mar Vista Investment Partners, LLC, an investment management company, released its “Mar Vista U.S. Quality Strategy” fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. US equities experienced a strong momentum in 2025 and marked their second consecutive year of double-digit gains. The market witnessed one of the fastest recoveries following its […]

Description: Johnson & Johnson (NYSE: JNJ) announced today that 11 abstracts featuring new data on its robust portfolio and pipeline in neuropsychiatry will be presented at the 64th Annual Meeting of the American College of Neuropsychopharmacology (ACNP), held from January 12-15, in Nassau, Bahamas. Presentations include the latest research from across the Company's neuropsychiatry portfolio, including major depressive disorder (MDD) and treatment-resistant depression (TRD), as well as preclinical and transl

Description: PFE's oncology results should reflect steady growth from Seagen ADCs and key brands, offset by pricing and competitive pressures.

Description: JNJ's MedTech unit is gaining momentum from cardiovascular strength and new products, even as China pressure lingers into the next quarter.

Description: The pharmaceutical giant said it will build production facilities in North Carolina and Pennsylvania as part of its broader $55 billion investment commitment.

Description: More than 60 straight years of increasing dividends reflects a strong commitment behind these stocks.

Description: AbbVie has agreed to cut some drug prices and invest $100 billion in the U.S. in exchange for an exemption from some tariffs. The pharma company said in a statement late Monday that it had struck a deal with the Trump administration to lower Medicaid prices and pour the money into U.S. research and development. AbbVie will also expand its direct-to-patient offerings of certain drugs on the government portal TrumpRx.

Description: Johnson & Johnson (JNJ) closed the most recent trading day at $209.72, moving +2.61% from the previous trading session.

Description: Retiring at 67 with $6,500 in monthly income places you solidly in middle-class territory, but the financial reality behind that figure is more nuanced than it appears. With average Social Security benefits at $2,017 per month in 2026, a retiree targeting $6,500 needs to generate roughly $4,483 monthly—or $53,796 annually—from personal savings and investments. The ... What $6,500 a Month Really Looks Like in Retirement at 67

Description: At 60 years old with $2 million saved, you can safely say that you are in a good position that most people will never reach. At this point, the question in your mind should shift from whether you have enough to retire to how much income you can generate from a $2 million portfolio to ... How Much Monthly Income Does a $2 Million Portfolio Produce at Age 60?

Description: Monday is the first day of J.P. Morgan’s annual healthcare investor conference, which draws thousands of investors, analysts, and executives to San Francisco each year. There is ample precedent: Last year, Johnson & Johnson announced a $14.6 billion deal to acquire Intra-Cellular Therapeutics on the first day of the gathering. The Wall Street Journal reported last week that Merck was in talks to buy the biotech Revolution Medicines for roughly $30 billion, but as of late morning, no such agreement had been announced.

Description: Distalmotion Secures Strategic Investment to Advance ASC Expansion of the DEXTER® Robotic Surgery System Distalmotion, the global MedTech company empowering access to robotic surgery in outpatient sites of care, today announced a strategic investment from Johnson & Johnson, through its corporate venture capital organization, Johnson & Johnson Innovation – JJDC, Inc (“JJDC”). This investment follows the company’s successful 2025 closing of its $150M Series G round, led by Revival Healthcare Capit

Description: Johnson & Johnson (NYSE:JNJ) today announced new longer follow-up results from the investigational Phase 1b/2 OrigAMI-1 study evaluating amivantamab-vmjw, a bispecific antibody targeting epidermal growth factor receptor (EGFR) and MET, in combination with FOLFOX or FOLFIRI chemotherapy in patients with RAS/BRAF wild-type metastatic colorectal cancer. The encouraging anti-tumor activity, durable responses, and low rates of treatment-related discontinuations observed in this study support further

Description: Eli Lilly (NYSE: LLY) and Johnson & Johnson (NYSE: JNJ) both delivered strong third-quarter results, but their earnings revealed two fundamentally different healthcare businesses. Lilly rode explosive GLP-1 drug demand to 53.9% revenue growth. Johnson & Johnson leaned on diversification across medical devices, pharmaceuticals, and consumer health to post 6.8% growth. GLP-1 Momentum Versus Diversified ... The GLP-1 Blockbuster Maker Widens Its Lead as the Diversified Healthcare Giant Posts Steady

Description: ↗️ Intel (INTC): President Trump said late Thursday he had "just finished a great meeting" with CEO Lip-Bu Tan. Shares leapt 11% Friday. The U.S. has said it will convert around $9 billion in federal grants into a 10% equity stake in the chip maker.

Description: Drug discounts trade for tariff relief

Description: Legend Biotech Corporation (NASDAQ:LEGN) is one of the 12 Stocks that Will Bounce Back According to Wall Street Analysts. On December 17, Cantor Fitzgerald maintained its Overweight rating on Legend Biotech Corporation (NASDAQ:LEGN) with a price target of $74. The firm said the stock has come under pressure because of concerns about competition, even though […]

Description: Add some stability to your holdings with these healthcare giants.

Description: What Is Driving the Updated Fair Value Estimate? The new fair value estimate for Johnson & Johnson has edged from about US$209.29 to about US$211.38 per share, a small shift that reflects a slightly higher revenue growth assumption at about 5.34% while the discount rate stays essentially unchanged at about 6.96%. This fine tuning lines up with recent Street commentary that highlights above consensus Q3 results, confidence in the product pipeline, and expectations that the planned orthopedics...

Description: JNJ cuts U.S. drug prices under a Trump deal, gains a tariff reprieve, and accelerates a $55 billion push to expand domestic manufacturing.

Description: Bayer AG enters into collaborations to develop a heart-targeted siRNA therapy and AI technology, expanding its push into next-gen genetic medicines.

Description: ISRG is positioning da Vinci 5 as a TAM expander, targeting cardiac surgery long term while advancing near-term regulatory steps in general surgery.

Description: ABBV's Q4 outlook hinges on surging Skyrizi and Rinvoq demand, as investors watch immunology sales to offset Humira's past loss of exclusivity.

Description: Investing.com -- HSBC has identified 11 U.S. stocks that could outperform as the fourth-quarter earnings season begins, highlighting companies with strong competitive positions, improving fundamentals and exposure to long-term themes.

Description: The New Jersey pharma will now offer some of its branded medicines on the US government-created DTC platform, TrumpRx.gov.

Description: Kenvue is gearing to release its fourth-quarter results shortly, and analysts expect its earnings to fall in low-double-digits.

Description: Insmed’s Brinsupri blew past consensus estimates in its first full quarter on the market. Elsewhere, J&J inked pharma’s latest deal with the Trump administration and Madrigal licensed a Pfizer drug.

Description: Johnson & Johnson is gaining momentum as innovative medicines and a strengthening MedTech business support growth despite key patent headwinds.

Description: Johnson & Johnson has said it will lower the price of some medications sold to U.S. consumers, making it the latest pharmaceutical company to form a business agreement with the Trump administration. “Today’s agreement shows that when the public and private sectors work together towards shared goals, we can deliver real results for patients and the U.S. economy,” Johnson & Johnson’s chief executive Joaquin Duato said in a statement late Thursday. Johnson & Johnson also said it will participate in the proposed patient platform, TrumpRx.gov, which will allow patients to buy drugs at “significantly discounted rates.”

Description: The agreement provides Johnson & Johnson’s pharmaceutical products an exemption from tariffs, the company said.

Description: Jan 8 () - Johnson & ​Johnson ‌said on Thursday ‌it has reached a ⁠agreement ‌with U. President ‍Donald Trump's administration to ​cut ‌drug prices for Americans in exchange ⁠for exemptions ​from ​U.

Description: NEW BRUNSWICK, N.J., January 09, 2026--Johnson & Johnson (NYSE: JNJ) (the "Company"), healthcare’s leading, most comprehensive innovation powerhouse, today announced a voluntary agreement with the Trump Administration to improve access to medicines and lower costs for millions of American patients. The joint agreement meets the requests laid out by President Trump to the industry and provides the Company’s pharmaceutical products an exemption from tariffs1.

Description: JNJ is leaning on Innovative Medicine growth and MedTech momentum to offset the Stelara patent cliff as it heads into 2026.

Description: NEW YORK, January 08, 2026--GenNx360 Capital Partners ("GenNx360"), a New York City-based private equity firm investing in middle-market industrial and business services companies, today announced the appointment of Hany Salama as Chief Executive Officer of its portfolio company, Nutra-Med Packaging ("Nutra-Med" or the "Company"), one of the leading contract development and manufacturing organizations serving the health, wellness, and pharmaceutical sectors. Mr. Salama succeeds Kunal Gupta, effe

Description: Dividend aristocrats get plenty of attention, but most of the time the spotlight falls on the big names like Johnson & Johnson (NYSE:JNJ), Coca-Cola (NYSE:KO), and Procter & Gamble (NYSE:PG), among others. These are the names and stocks that dominate articles around dividend growth and, unsurprisingly, fill up income portfolios around the country. There is ... The Dividend Aristocrats No One’s Talking About (And Their 30+ Year Track Records)

Description: Johnson & Johnson (JNJ) shares are in focus after two pipeline updates: a Phase 2b win for nipocalimab in systemic lupus erythematosus and an FDA De Novo submission for the OTTAVA robotic surgical system. See our latest analysis for Johnson & Johnson. Those pipeline updates sit alongside a steady share price trend, with Johnson & Johnson’s stock at US$207.49 and a 90 day share price return of 8.59%, while the 1 year total shareholder return of 50.31% suggests stronger momentum over a longer...

Description: PITTSBURGH, January 08, 2026--RQM+, a leading global MedTech service provider (CRO), today announced that Ross D. Segan, M.D., MBA, FACS, has joined its board of directors. Dr. Segan is a physician–executive and MedTech strategist with senior leadership experience at the U.S. Food and Drug Administration (FDA), Johnson & Johnson, Olympus, Covidien, and Vensana Capital, and currently serves as CEO of Medical Scientific Advisors, LLC.

Description: JNJ's Innovative Medicine segment shows resilience ahead of Q4 results, with key drugs driving growth despite Stelara biosimilars and Part D headwinds.

Description: Johnson & Johnson today announced Tony Hunter, Ph.D., of the Salk Institute as the recipient of the 2025 Dr. Paul Janssen Award for Biomedical Research. Dr. Hunter is honored for his role in the discovery of tyrosine kinases and protein-tyrosine phosphorylation as mechanisms for the malignant transformation of normal cells into cancer cells and other disease states.

Description: Johnson & Johnson (NYSE:JNJ) is one of the stocks Jim Cramer offered insights on. Cramer highlighted the company’s latest spin-off plans for one of its divisions, as he commented: “The fastest grower, the best opportunity here would not be Eli Lilly, which has moved a great deal and I still like, but Johnson & Johnson. […]

Description: Collaboration will combine Lexeo expertise in cardiac genetic medicine with Johnson & Johnson’s expertise in cardiovascular therapeutics and circulatory technologies, including Impella™ heart pumps Agreement will enable accelerated development of a preclinical cardiac target using novel, localized routes of viral gene therapy administration NEW YORK, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel

Description: If you are wondering whether Kenvue's current share price reflects fair value or a potential opportunity, you are in the right place. The stock closed at US$16.74 with returns of a 3.0% decline over 7 days, a 0.1% decline over 30 days, a 3.3% decline year to date and a 17.4% decline over the last year, which may have shifted how investors think about its risk and return trade off. Recent coverage around Kenvue has focused on its position as a stand alone consumer health company following its...

Description: SAN MATEO, Calif., January 08, 2026--EpiBiologics, a leader in tissue-selective extracellular protein degradation, today announced the completion of a $107 million Series B financing co-led by GV (Google Ventures) and Johnson & Johnson, through its corporate venture capital organization, Johnson & Johnson Innovation – JJDC, Inc (JJDC).

Description: Leuven, Belgium. January 8, 2026. Onco3R Therapeutics, a clinical-stage immunology and oncology biotech company dedicated to transforming patients’ lives with best-in-class medicines, today announced the appointment of Lawrence M. Blatt, PhD, MBA as Chair of its Board of Directors. Dr. Blatt brings substantial expertise in strategic leadership, drug development and operations together with extensive experience, to guide and support Onco3R’s portfolio development and its next stage of growth. He

Description: In early January 2026, Johnson & Johnson reported that nipocalimab (Imaavy) met primary and key secondary endpoints in the Phase 2b JASMINE trial for systemic lupus erythematosus and moved the program into Phase 3, while also advancing its MedTech ambitions with an FDA De Novo submission for the OTTAVA robotic surgical system in general surgery. This combination of a potentially first-in-class FcRn blocker in SLE and a next-generation soft-tissue surgery robot underscores Johnson &...

Description: Health care stocks rose late Wednesday afternoon, with the NYSE Health Care Index adding 0.7% and th

Description: Johnson & Johnson (NYSE:JNJ) is included among the 14 Best Dividend Growth Stocks to Buy and Hold in 2026. On December 30, Barclays raised its price target on Johnson & Johnson (NYSE:JNJ) to $217 from $197 and kept an Equal Weight rating on the shares. The firm reviewed sales and prescription data through the final […]

Description: Imaavy will now progress to Phase III in SLE, though it will face strong competition from SLE market leader, Benlysta, if approved.

Description: Facial Skincare Market Facial Skincare Market Dublin, Jan. 07, 2026 (GLOBE NEWSWIRE) -- The "Facial Skincare Market by Type, Gender, Distribution Channel, Countries and Companies Analysis 2025-2033" has been added to ResearchAndMarkets.com's offering. The worldwide facial skincare market is anticipated to hit US$ 158.63 billion in 2033, increasing from US$ 98.56 billion in 2024, growing at a CAGR of 5.43% during 2025-2033. Increased consumer knowledge, the need for anti-aging, and new developmen

Description: J&J's phase IIb JASMINE study on nipocalimab meets key endpoints in systemic lupus erythematosus, supporting plans to advance the drug into phase III.

Description: Alumis shares soar as the biotech firm’s envudeucitinib meets all primary and secondary endpoints in a Phase 3 trial. Here’s how you should play ALMS shares in 2026.

Description: The Dow Jones Industrial Average is on the verge of another big milestone and could continue to climb as the rally broadens.

Description: Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Description: AMGN's $840M buyout of Dark Blue Therapeutics adds a preclinical AML degrader, bolstering its oncology pipeline.

Description: NEW BRUNSWICK, N.J., January 07, 2026--Johnson & Johnson today announced that the company has submitted the OTTAVA™ Robotic Surgical System to the U.S. Food and Drug Administration (FDA) in an application for De Novo classification. Leveraging data from the Investigational Device Exemption (IDE) study, the company has applied for marketing authorization in multiple procedures in general surgery within the upper abdomen.

Description: (Updates with BioNTech response in the sixth paragraph.) Bayer's Monsanto unit filed patent infri

Description: It's not too late to reshape and optimize your portfolio for what could be a very different market environment than last year's.

Description: Bayer's Monsanto unit filed patent infringement lawsuits Tuesday against COVID-19 vaccine makers Pfi

Description: If you are wondering whether Johnson & Johnson shares still offer solid value after a strong run, this article will walk through what the current price might be implying about the company. The stock last closed at US$204.79, with returns of 1.4% over 30 days and 44.3% over 1 year, which may have changed how some investors think about both its potential and its risks. Over the past year, Johnson & Johnson has remained in focus as a large healthcare name. Investors have been watching how it...

Description: Biotech stock Alumis catapulted on Tuesday after the company unveiled promising results that could help it compete against J&J in psoriasis.

Description: Investments from Novo Nordisk, Johnson & Johnson, and Fujifilm are driving warehouse demand as pharmaceutical manufacturing returns to U.S. soilRALEIGH, N.C., Jan. 06, 2026 (GLOBE NEWSWIRE) -- North Carolina attracted $10.8 billion in life sciences manufacturing investments in 2024, anchored by major pharmaceutical projects that are transforming the Research Triangle's industrial real estate market, according to new analysis from WareCRE, a B2B industrial real estate marketplace. The investments

Description: J&J's diversified pharma and MedTech strength stacks up against AstraZeneca's oncology-led growth as investors weigh stability versus faster expansion.

Description: Johnson & Johnson (NYSE: JNJ) today announced positive topline results from the Phase 2b JASMINE (NCT04882878) study of adults living with systemic lupus erythematosus (SLE) and the initiation of a Phase 3 program. The JASMINE study met the primary endpoint (percentage of patients achieving Systemic Lupus Erythematosus Responder Index [SRI-4]a composite response at Week 24 with statistical significance compared with placebo), and key secondary and exploratory endpoints, including those indicatin

Description: Novel immunotherapy combination regimen brings together two complementary therapies to improve outcomes for people living with multiple myeloma as early as second line1 The application is supported by data from the Phase 3 MajesTEC-3 study demonstrating a statistically significant improvement in progression-free and overall survival compared to standard treatment1 Beerse, Belgium, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Johnson & Johnson today announced the submission of a Type II variation applicatio

Description: Pharmaceutical companies are getting a fresh look for a range of drugs in development, plus a regulatory reprieve.

Description: Eli Lilly highlights how AI is transforming healthcare, from drug discovery to diagnostics, turning defensive medical stocks into growth plays for 2026.

Description: In the closing of the recent trading day, Johnson & Johnson (JNJ) stood at $204.31, denoting a -1.47% move from the preceding trading day.

Description: Biotech stock GH Research catapulted Monday after the FDA gave it the go-ahead to resume testing its depression drug.

Description: These companies pay high-yielding and steadily rising dividends.

Description: These five top Dividend Kings with yields up to 7% looked poised to deliver strong total return and passive income in 2026.

Description: LLY, MDT, ISRG, REGN and JNJ are five defensive medical stocks using AI to drive growth, diagnostics and innovation into 2026.

Description: Novo Nordisk officially began marketing the pill version of its popular weight loss drug. Elsewhere, Sanofi bought a vaccine maker and an eczema therapy J&J acquired in a billion-dollar deal failed a key test.

Description: They can help you weather the storm.

Description: These dividends should continue growing.

Description: Novo Nordisk cuts Wegovy prices in China, which may shift investor focus toward diversified healthcare ETFs.

Description: NEW BRUNSWICK, N.J., January 02, 2026--Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the first quarter of 2026 of $1.30 per share on the company’s common stock. The dividend is payable on March 10, 2026 to shareholders of record at the close of business on February 24, 2026. The ex-dividend date is February 24, 2026.

Description: ABBV's neuroscience franchise now drives more than 17% of revenues, with strong Botox, Vraylar and migraine drug sales fueling double-digit growth.

Description: These income stocks could be great buys to add to your portfolio.

Description: High-yielding Dow stocks outperformed the broader market this year. Will new Dow dogs Home Depot, Nike, and UnitedHealth keep the streak going?

Description: Halozyme Therapeutics, Inc. (NASDAQ:HALO) is one of the best affordable stocks with good earnings growth for 2026. Halozyme Therapeutics, Inc. (NASDAQ:HALO) announced on December 18 that Johnson & Johnson received approval from the U.S. Food and Drug Administration (FDA) for RYBREVANT FASPRO, co-formulated with ENHANZE® for people with epidermal growth factor receptor (EGFR)-mutated locally advanced or […]

Description: AbbVie Inc. (NYSE:ABBV) is one of the best stocks for the next decade. On December 12, Morgan Stanley raised the firm’s price target on AbbVie to $269 from $261 with an Overweight rating on the shares. Earlier on December 10, HSBC upgraded AbbVie to Buy from Hold with a price target of $265, which was […]

Description: List prices to rise an average of 4% despite federal pressure to curb costs.

Description: The average brokerage recommendation (ABR) for Johnson & Johnson (JNJ) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?

Description: Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Description: The Dow Jones' top five stocks of the year included two names investors may not have expected to find next to AI giants like Nvidia and IBM.

Description: BAYRY shares have risen 121.6% in a year as new FDA approvals, pipeline wins and litigation updates fuel a sharp turnaround.

Description: BSX's $50B cardiovascular business aims to outpace market growth across EP, WATCHMAN, ICTx and more.

Description: Johnson & Johnson (NYSE:JNJ) is included among the 14 Best Pharma Dividend Stocks to Buy in 2026. On December 26, Johnson & Johnson (NYSE:JNJ) said it ended a mid-stage study of an experimental drug for patients with moderate to severe atopic dermatitis. The decision followed an interim analysis showing the treatment did not meet its […]

Description: Investors seeking reliable dividends will find that this trio of healthcare stocks offers an exciting combination of safety, growth, and income.

Description: Three dividend-paying pharma stocks stand out for steady 2026 gains as innovation, pricing deals and resilient drug demand support returns.

Description: IBM leads a list of high-yield S&P 500 picks for 2026 as steady cash flow, dividends and AI exposure appeal amid market volatility.

Description: The deal adds early-stage candidates for breast, lung, and other tumour types, using RIPTAC technology, to J&J’s pipeline.

Description: Health care stocks were mixed late Monday afternoon, with the NYSE Health Care Index fractionally hi

Description: High-yielding Dow stocks outperformed the broader market this year. Will new Dow dogs Home Depot, Nike, and UnitedHealth keep the streak going?

Description: High-yield S&P 500 stocks are gaining traction for 2026 as AI investment accelerates and investors seek income amid trade and geopolitical uncertainty.

Description: All three are buys, but for different reasons.

Description: Castle Biosciences surged 77.9% after a Zacks upgrade, highlighting how the firm's stock picks outpaced the broader market in recent months.

Description: NEW BRUNSWICK, N.J., December 29, 2025--Johnson & Johnson (NYSE: JNJ) (the "Company") today announced the successful completion of its acquisition of Halda Therapeutics OpCo, Inc. ("Halda"), a clinical-stage biotechnology company with a proprietary Regulated Induced Proximity TArgeting Chimera (RIPTAC™) platform to develop oral, targeted therapies for multiple types of solid tumors, including prostate cancer, for $3.05 billion in cash.

Description: Atai Beckley N.V. (NASDAQ:ATAI) is among the Best Get Rich Fast Stocks to Buy Right Now. On December 23, Justin Walsh from JonesTrading initiated coverage on Atai Beckley N.V. (NASDAQ:ATAI) with a ‘Buy’ rating and a price target of $16, according to TheFly. This translates to an upside potential of nearly 282%. According to the […]

Description: US equity benchmarks ended little changed Friday as activity remained subdued after the Christmas br

Description: Health care stocks were edging up late Friday afternoon with the NYSE Health Care Index and the Stat

Description: US benchmark equity indexes were mixed intraday as activity remained subdued after the Christmas bre

Description: Health care stocks declined Friday afternoon, with the NYSE Health Care Index and the State Street H

Description: Johnson & Johnson (JNJ) said Friday it decided to terminate a mid-stage trial of one of its experime

Description: All three major US stock indexes were edging lower in midday trading on Friday following the Christm

Description: Investors gave been rotating away from technology. This biotech stock has rallied into a buy zone amid sharp earnings growth.

Description: JNJ's rapidly advancing pipeline, new drug approvals and expanding cancer and neuroscience portfolio could fuel growth through the next decade.

Description: Pfizer faces revenue pressure from 2026-2030 LOEs but is betting on a strengthened oncology and obesity pipeline to fuel sustainable post-LOE growth.

Description: Invesco leads Zack' list of five high-yield S&P 500 stocks, highlighting dividend strength and steady income potential for 2026.

Description: Meridian Funds, managed by ArrowMark Partners, released its “Meridian Hedged Equity Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. In the quarter, the market is more focused on the tailwind of policy easing than the headwind of weakening fundamentals, resulting in substantial gains despite stagflation emerging as a key concern. […]

Description: Johnson & Johnson (JNJ) has been quietly grinding higher, with shares up sharply over the past year even after a recent pullback. Investors are now asking whether this run still leaves meaningful upside. See our latest analysis for Johnson & Johnson. Momentum still looks constructive here, with the share price up meaningfully over the past year and a strong 90 day share price return of 16.46 percent supporting a 1 year total shareholder return of 45.41 percent. If J&J’s steady climb has you...

Description: Health care stocks were mixed late Tuesday afternoon, with the NYSE Health Care Index fractionally h

Description: BMY has agreed to supply Eliquis free of charge to Medicaid starting in 2026 and will also donate seven tons of the active pharmaceutical ingredient used in Eliquis.

Description: Health care stocks were mixed Tuesday afternoon, with the NYSE Health Care Index increasing 0.1% and

Description: High-yield S&P 500 stocks IVZ, JNJ, NI, BG and MS offer steady income, compounding returns and portfolio stability as moderate growth and easing inflation shape 2026.

Description: Johnson & Johnson wins EU approval for Tremfya in pediatric plaque psoriasis, making it the first IL-23 inhibitor cleared for any pediatric condition.

Description: Company vows appeal after jury decision

Description: A Baltimore jury found Johnson & Johnson liable for failing to warn about asbestos risks tied to talc-based baby powder.

Description: TPB, JNJ and NEE highlight how defensive stocks can offer stability and steady growth potential amid rising uncertainty for 2026.

Description: These four companies have increased their dividends annually for decades. And they will mostly likely boost their payouts again in the coming year.

Description: Five big drugmakers, including LLY and JNJ, are riding innovation, dealmaking and pipeline momentum that could help them keep outperforming in 2026.

Description: The verdict is the latest in a string of legal judgments the company is facing over claims its talc products cause cancer.

Description: These low-risk dividend stocks have the potential to produce a more than 100% total return over the next decade.

Description: Company plans to appeal Maryland jury ruling tied to asbestos exposure claims.

Description: Johnson & Johnson (JNJ) has been ordered by a Baltimore jury to pay more than $1.5 billion to a sing

Description: JNJ wins FDA approval for a subcutaneous version of Rybrevant, cutting treatment time to minutes and boosting convenience across NSCLC indications.

Description: BALTIMORE, December 23, 2025--A Baltimore city jury has returned a verdict in favor of Cherie A. Craft, awarding her over $1.5 billion after finding that Johnson & Johnson and its subsidiaries exposed her to asbestos through talc-based personal care products and caused her to develop peritoneal malignant mesothelioma, an incurable cancer. The verdict is believed to be the largest ever returned against Johnson & Johnson for a single plaintiff.

Description: Health care stocks advanced late Monday afternoon with the NYSE Health Care Index rising 0.6% and th

Description: Health care stocks advanced Monday afternoon, with the NYSE Health Care Index up 0.5% and the State

Description: XLV and similar healthcare ETFs are gaining momentum as strength in biotech, increased AI adoption, and rising defensive demand position the sector for year-end leadership.

Description: J&J has been trading above its 50- and 200-day SMAs for six months as strong 2025 execution, new drugs and pipeline progress support bullish momentum.

Description: Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Description: Investor interest is building ahead of Johnson & Johnson’s Q4 earnings, backed by positive analyst sentiment.

Description: Microsoft rewards long-term investors in a variety of ways.

Description: Kura Oncology, Inc. (NASDAQ:KURA) is one of the stocks Jim Cramer offered insights on. When a caller highlighted the company’s $135 million milestone payment owing to its U.S. commercial sale of KOMZIFTI, Cramer commented: “That’s a lot. That is a lot… Now, just understand that, yeah, they are milestone payments, not actual. Now, here’s what […]

Description: For as long as most of us can remember, the idea of retiring with $2.5 million in the “bank,” is something of a dream. The belief that this amount of money would guarantee decades of worry-free living feels like all of the stars aligning after decades of hard work, disciplined savings, and investing, and the ... What Retirement Really Looks Like With $2.5 Million in Savings

Description: People are working past the typical retirement age of 65, which means there are five generations in the workplace, all with different work and management styles. The next two decades will bring even more consequential change, with artificial intelligence driving much of the reshaping of work. It will have an impact on the role of managers, how organizations measure business outcomes and accelerate tasks that once took months.

Description: Johnson & Johnson’s narrative in the market is shifting as its fair value estimate edges up from $202.54 to $209.29 and revenue growth expectations tick higher from 5.23% to about 5.32%, reflecting growing confidence in the company’s long term trajectory. Behind these moves is a more constructive Wall Street view on J&J’s portfolio, from the planned orthopedics separation to resilient demand in Innovative Medicine and MedTech, alongside easing concern around talc litigation and a belief that...

Description: ST. PAUL, Minn., December 20, 2025--A Minnesota jury awarded $65.5 million to a 37-year-old mother of three minor children after finding in her favor in a lawsuit against Johnson & Johnson, concluding that the company’s talc products exposed her to asbestos and contributed to her developing peritoneal mesothelioma, a cancer of the peritoneal lining in the stomach.

Description: Dow Jones stock Merck and eight other bellwether pharma companies struck drug-pricing agreements with the Trump administration on Friday.

Description: The most recent pledges mean 14 of the 17 drugmakers targeted by Trump this summer have agreed to lower prices for the Medicaid program for low-income and disabled people, sell discounted drugs directly to consumers and launch new medicines for the same prices in the US as they do abroad. “American drug prices will come down fast and furious, and will soon be among the lowest in the developed world,” Trump said during an event in the Oval Office.

Description: Johnson & Johnson (NYSE:JNJ) is one of the stocks Jim Cramer talked about recently. Cramer mentioned the stock during the episode and said: “These groups were the salvation of this market when the year of magical investing ended, and the super speculative stocks started coming back to earth, they’re still doing it, followed by the […]

Description: The Trump administration has talked tough on drug prices, but the impact of its deals with drugmakers so far has been limited.

Description: Pharma ETFs like IHE are gaining traction as drugmakers pledge $370 billion to U.S. projects, fueling a new investment super-cycle heading into 2026.

Description: We recently published 12 Stocks on Jim Cramer’s Radar. Johnson & Johnson (NYSE:JNJ) is one of the stocks on Jim Cramer’s radar. Healthcare giant Johnson & Johnson (NYSE:JNJ) factored into the discussion after Cramer and his co-hosts discussed Pfizer and Merck. The firm’s shares are up by 46% year-to-date and have had a good December […]

Description: The global pulmonary embolism market is poised for growth from 2025 to 2035, fueled by rising cases of deep vein thrombosis (DVT) and pulmonary embolism (PE) due to escalating obesity rates and sedentary lifestyles. Key drivers include improved diagnostics, Direct Oral Anticoagulants (DOACs), and heightened awareness. Despite the growth, high treatment costs and complications, such as bleeding risks, pose significant challenges, especially in lower-income regions. Top market players include Sano

Description: JNJ wins FDA approval for a subcutaneous version of Rybrevant, cutting treatment time to minutes and boosting convenience across NSCLC indications.

Description: J&J, ImmunityBio and Foghorn Therapeutics stand out as oncology players amid rapid innovation in cancer care with advancing pipelines, approvals and partnerships.

Description: Johnson & Johnson (NYSE: JNJ) – Today, Johnson & Johnson MedTech, a leader in neurovascular care, announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for the TRUFILL n‑BCA Liquid Embolic System for embolization of the middle meningeal artery (MMA) for the treatment of symptomatic subacute and chronic Subdural Hematoma (cSDH) as an adjunct to surgery.

Description: Social Security’s cost-of-living adjustments swing wildly year to year. The 2025 COLA came in at 2.5%, down from 3.2% in 2024 and 8.7% in 2023. For retirees counting on predictable income growth, this volatility creates planning challenges. The solution lies in dividend stocks that deliver consistent income growth regardless of Social Security. These five stocks ... 5 Dividends That Beat Social Security’s Unpredictable COLA Adjustments

Description: Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Johnson & Johnson has received approval from the U.S. Food and Drug Administration (FDA) for RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj), which is co-formulated with ENHANZE® for patients with epidermal growth factor receptor (EGFR)-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC).1 RYBREVANT FASPRO™ is approved across all indications of RYBREVANT® (amivantamab-vmjw) and represents the

Description: Johnson & Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Administration (FDA) approved RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj), the first and only subcutaneously (SC) administered therapy for patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC).1 RYBREVANT FASPRO™ is approved across all indications of RYBREVANT® (amivantamab-vmjw).

Description: Johnson & Johnson (NYSE:JNJ) is included among the 12 Best Dogs of the Dow to Invest in. On December 15, BofA raised its price target on Johnson & Johnson (NYSE:JNJ) to $220 from $204. The firm kept a Neutral rating. The firm says J&J’s premium multiple “looks appropriate for its growth plus asset mix.” It […]

Description: IRVINE, Calif., December 17, 2025--RIS Rx, a healthcare technology company offering gross-to-net (GTN) revenue protection and saving more than $1 billion for the world’s leading pharmaceutical manufacturers, today announced the appointment of Stuart McGuigan to its Board of Directors.

Description: Secondary offerings from biotechs Immunovant, Kymera Therapeutics, and Wave Life Sciences prompted some huge insider buying recently.

Description: Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Description: COPENHAGEN, Denmark, December 17, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that, following the recent appointment of Anne Louise Eberhard as new Chair of the Board of Directors, and in accordance with the Company’s Articles of Association, the Board has convened and has appointed Ms. Heidi Hunter as new Vice Chair. Ms. Hunter has been a member of the board since 2023. She has over 25 years of industry experience, working across the pharmaceutical value chain, from clinical and comm

Description: Today, Dec. 16, 2025, Pfizer's shrinking COVID cash flows could mean little growth next year as M&A bets will take time to deliver.

Description: Large M&A transactions and bidding wars for Metsera and Avadel announced in H2 2025 reflect a need for large pharma companies to replenish pipelines through M&A ahead of looming patent cliffs.

Description: These companies have stood the test of time and survived many previous recessions.

Description: S&P Global (NYSE: SPGI) announced today that its Board of Directors has approved the addition of Mr. Hubert Joly to the Board, effective January 2, 2026.

Description: Cradle, an enterprise-grade AI software platform, today announced a series of milestones that signal a new phase of growth. The company saw rapid adoption across the pharma industry, with Cradle now running 50+ projects and powering drug discovery programs for six of the top 25 big pharma companies, including Johnson & Johnson, Abbvie, and Novo Nordisk. To continue expanding product capabilities and meet surging global demand, the company has doubled headcount across all departments and expanded

Description: The Icee maker expects to accrue $20 million in annualized savings from a business transformation plan aimed at simplifying production and optimizing distribution.

Description: The FDA contacted J&J right after ASH to discuss using a special fast pass on a multiple myeloma regimen. Elsewhere, a new cell therapy player emerged and Sanofi cut deals with two startups.

Description: NEW BRUNSWICK, N.J., December 15, 2025--Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Wednesday, January 21st to review fourth-quarter results. Joaquin Duato, Chairman and Chief Executive Officer, Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Darren Snellgrove, Vice President, Investor Relations will host the call. The question and answer portion of the call will also include additional members of Johnson & Johns

Description: Fred Alger Management, LLC ("Alger"), a privately held growth equity investment manager, today announced the quarterly rebalancing of the Alger Russell Innovation Index ("Index"). Following the close of trading on Friday, December 19, 2025, the Index will be rebalanced, and the following changes will be effective.

Description: Akeega’s indicated usage now spans across mCSPC and mCRPC, widening the drug’s future market potential.

Description: Johnson & Johnson (JNJ) remains a stable, relatively low-risk stock, though its upside appears limit

Description: Ahead of the new year, Yahoo Finance Markets and Data Editor Jared Blikre takes a closer look at some of the Dow Jones Industrial Average's (^DJI) best performers in 2025: Caterpillar (CAT), Goldman Sachs (GS), Johnson & Johnson (JNJ), and IBM (IBM). To watch more expert insights and analysis on the latest market action, check out more Morning Brief.

Description: JNJ secures FDA approval to expand Akeega into earlier-stage prostate cancer, backed by strong phase III data and a first-of-its-kind precision combo.

Description: Merck secures a positive CHMP opinion to expand Winrevair's PAH use, potentially broadening treatment to adult patients across WHO FC II-IV.

Description: Based on the average brokerage recommendation (ABR), Johnson & Johnson (JNJ) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

Description: Liquidia shares have surged 43.9% since an October upgrade, as Zacks highlights stock wins and portfolio results despite a volatile market.

Description: Link Cell Therapies ("Link"), an oncology cell therapy company, today announced its official launch from stealth with a $60 million Series A financing that was led by Johnson & Johnson, through its corporate venture capital organization, Johnson & Johnson Innovation – JJDC, Inc. , with participation from founding investors Samsara BioCapital and Sheatree Capital, as well as Wing Venture Capital and other new strategic and financial investors.

Description: Retirement portfolios need growing income that outpaces inflation and safety that lets you sleep at night. The best retirement dividend stocks build reliable income streams that compound for decades. These companies raise dividends through recessions, market crashes, and business disruptions. We ranked them by dividend growth consistency, payout sustainability, and business resilience heading into 2026. ... The Best Dividend Stocks for Retirement Portfolios in 2026

Description: The Social Security Administration announced in October that beneficiaries will receive a 2.8% cost-of-living adjustment (COLA) in 2026, following a 2.5% increase in 2025. While these adjustments help protect purchasing power for 71 million Americans, dividend growth stocks have historically delivered substantially higher annual increases. Five blue-chip companies with multi-decade dividend growth streaks have consistently ... Forget the 2.8% Social Security Increase. These Aristocrats Pay You 4

Description: Building wealth through dividends requires more than chasing high yields. The path to “getting rich” combines meaningful current income with consistent dividend growth, backed by sustainable business fundamentals. These five stocks deliver that combination, each offering distinct advantages for compounding wealth over time. #5: Procter & Gamble (PG): The Steady Compounder Procter & Gamble earns ... 5 Dividend Powerhouses That Could Transform Your Portfolio Into a Wealth-Building Machine

Description: Johnson & Johnson (NYSE:JNJ) announced today the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for AKEEGA® (niraparib and abiraterone acetate dual-action tablet) plus prednisone for the treatment of patients with BRCA2-mutated metastatic castration-sensitive prostate cancer (mCSPC).1 Patients with BRCA mutations often have more aggressive forms of prostate cancer leading to poor prognosis, representing a significant unmet need not addressed by prev

Description: They might be on to something.

Description: Wondering if Johnson & Johnson is still a steady blue chip or a quietly undervalued opportunity? Let us unpack what the current share price really implies about its long term value. After drifting for a while, J&J has pushed higher recently, with the stock up 3.7% over the last week, 8.3% over the past month, and an impressive 45.8% year to date, translating into a 48.0% gain over the last year. Those kinds of moves suggest the market is rethinking its risk and growth narrative for this...

Description: Dividend investing rewards patience. The best dividend stocks don’t just pay consistently—they raise payouts year after year, compounding income for shareholders who stay the course. Among thousands of publicly traded companies, only a select few have proven they can grow dividends through recessions, market crashes, and industry upheaval. We ranked these six proven dividend winners ... Proven Income Generators: Ranking the Most Reliable Dividend Growth Stocks

Description: AMGN gains momentum as Uplizna wins FDA approval for generalized myasthenia gravis, adding a twice-yearly dosing option in a crowded autoimmune market.

Description: AbbVie dips below its 50-day SMA, but strong immunology momentum and a resilient long-term trend keep the story compelling.

Description: In the most recent trading session, Johnson & Johnson (JNJ) closed at $210.01, indicating a +1.68% shift from the previous trading day.

Description: The 67th American Society of Hematology (ASH) Annual Meeting, held December 6-9, 2025, in Orlando, Florida, showcased groundbreaking clinical advances in multiple myeloma treatment from leading biopharmaceutical companies. The conference featured unprecedented efficacy data demonstrating potential functional cures and innovative approaches across novel immunotherapies, bispecific antibodies, and next-generation targeted agents, signaling a major shift in how the disease is managed.

Description: Health care stocks rose late Thursday afternoon, with the NYSE Health Care Index up 0.9% and the Sta

Description: Health care stocks rose Thursday afternoon, with the NYSE Health Care Index and the State Street Hea

Description: After recently coming under pressure, these three dividend stocks have both yield and rebound potential.

Description: Tecvayli + Darzalex delivers superior efficacy in early relapsed MM, positioning J&J to dominate the R/R market.

Description: AVGO draws attention as analysts spotlight its AI-driven momentum alongside notable updates on XOM, JNJ, ITIC and FRD.

Description: Johnson & Johnson recently reported Phase 3 data showing that its TECVAYLI plus DARZALEX FASPRO combination cut the risk of disease progression or death for relapsed or refractory multiple myeloma patients and secured US FDA Breakthrough Therapy Designation, while updated CARVYKTI results pointed to durable, treatment-free remissions with earlier-line use. Together, these oncology data reinforce Johnson & Johnson’s push into next-generation blood cancer therapies, potentially reshaping...

Description: Johnson & Johnson (NYSE:JNJ) is included among the 15 Best Stocks to Buy for the Long Term. On December 5, Guggenheim boosted the firm’s price target on Johnson & Johnson (NYSE:JNJ) to $227 from $206 and maintained a Buy rating on the shares. According to the analyst research note, the update came after the firm […]

Description: The year’s three largest acquisitions signal where pharma is willing to pay big for promising candidates.

Description: For investors approaching or in retirement, the right stock portfolio balances reliable income, low volatility, and consistent dividend growth. Among six prominent dividend-paying stocks, five stand out for their financial stability, income generation, and defensive characteristics that help retirees navigate market turbulence. The evaluation prioritized dividend yield, dividend growth consistency, earnings stability, low volatility measured ... 5 Dividend Powerhouses That Belong in Every Retire

Description: Broadcom rides surging AI semiconductor demand and VMware integration strength, even as margins tighten and debt remains a drag.

Description: Stock Market Today: The Dow Jones index rises Wednesday after the Fed rate cut. Microsoft stock sold off.

Description: Johnson & Johnson (NYSE:JNJ) is one of the best pharma stocks to invest in. Johnson & Johnson (NYSE:JNJ) announced on December 6 the updated results from the Phase 3 CARTITUDE-4 study that supported durable treatment-free remissions as early as second line treatment with CARVYKTI, reporting that the disease did not progress and no further treatment was […]

Description: JNJ and PFE battle patent cliffs and policy headwinds, but rising estimates and stronger 2025 momentum push JNJ ahead in this blue-chip faceoff.

Description: Johnson & Johnson (JNJ) has quietly ground higher, with the stock up roughly 7% over the past month and nearly 14% in the past 3 months, drawing fresh attention from income focused investors. See our latest analysis for Johnson & Johnson. Zooming out, that steady climb sits on top of a powerful backdrop, with a roughly 39% year to date share price return and a three year total shareholder return above 22% suggesting momentum is still firmly building as investors reassess Johnson & Johnson’s...

Description: Terns Pharmaceuticals shares jumped as much as 50% on news that cancer cell counts fell over 99% in nearly three-fourths of leukemia patients treated with the firm’s once-daily pill.

Description: Former military commanders, politicians, and one of Warren Buffett’s top stock pickers are also joining the advisory group.

Description: Pharma ETFs like IHE are poised to surge as the UK-US zero-tariff deal raises UK drug prices and strengthens major U.S. players' outlook.

Description: Blockbuster drugs are a major driver of the growth of healthcare stocks.

Description: Given the potential for a sizable sell-off, it makes sense for investors to move to S&P 500 Dividend Aristocrat stocks like these now.

Description: Johnson & Johnson (JNJ) said Tuesday that new data from a phase 3 study showed the combination of Te

Description: Teclistamab and daratumumab subcutaneous (SC) combination led to a statistically significant progression-free survival and overall survival advantage compared to standard treatment after three years of follow-up1 Combination regimen granted Breakthrough Therapy Designation by U.S. FDA BEERSE, BELGIUM, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Johnson & Johnson today announced new data from the investigational Phase 3 MajesTEC-3 study that demonstrate the potential of TECVAYLI®▼ (teclistamab) plus DARZAL

Description: Johnson & Johnson (NYSE:JNJ), the worldwide leader in multiple myeloma, today announced new data from the investigational Phase 3 MajesTEC-3 study that demonstrate the potential of TECVAYLI® (teclistamab-cqyv) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) as early as second line for patients with relapsed/refractory multiple myeloma (RRMM). Results show an 83% reduction in the risk of disease progression or death compared to standard regimens at nearly three-years follow-up (hazard

Description: Dividend growth investing has always had an appeal to people who are looking to boost their income, find stability in another unstable market, and build long-term wealth. However, 2026 is shaping up to be something of a turning point as a breakout year for this growing investment philosophy. Between market conditions, earnings trends, and a ... Why 2026 Could Be the Breakout Year for Dividend Growth Investors

Description: Retirees and older individuals are among the biggest demographics who tune into Jim Cramer’s Mad Money show. You may disagree with Cramer’s investing methodology and critique his failures, but it’s undeniable that his opinions have sway. And when it comes to long-term dividend investing, those opinions have held up quite well. Cramer’s opinionated takes often ... 2 Dividend Stocks That Jim Cramer Wants Every Retiree to Own

Description: J&J faces Stelara losses, Medicare shifts, talc suits and China pressure, banking on new products and expects segment growth to stay on track.

Description: Here's how you could copy the Oracle of Omaha in today's market.

Description: With market tailwinds building and optimism returning, these top-ranked ETFs can help investors capture momentum safely.

Description: Berkshire Hathaway's big shake-up across its corporate structure will see its top stock picker depart for JPMorgan.

Description: If you bought 10 shares of Johnson & Johnson (JNJ) stock 10 years ago, this is how much it would be worth today.

Description: JPMorgan Chase named tech billionaires Jeff Bezos and Michael Dell, plus an all-star cast of retired generals and politicians, to advise on its “Security and Resiliency Initiative.” The initiative aims to provide $1.

Description: Johnson & Johnson today announced final overall survival (OS) results from the Asia patients of the Phase 3 MARIPOSA study. Head-to-head comparison data versus osimertinib monotherapy showed amivantamab plus lazertinib led to a clinically meaningful OS improvement in the first-line treatment of Asian patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions (ex19del) or L858R substitution mutations. Median OS fo

Description: In a head-to-head trial, Lilly’s drug was as effective as Imbruvica at inducing responses and displayed certain safety advantages that could make it a preferred treatment in early lines of care.

Description: Johnson & Johnson (NYSE: JNJ) announced today updated results from the Phase 3 CARTITUDE-4 study supporting durable treatment-free remissions as early as second line treatment with CARVYKTI® (ciltacabtagene autoleucel; cilta-cel). In 80 percent of as-treated patients with relapsed or refractory multiple myeloma (RRMM) and standard-risk cytogenetics who were treated with CARVYKTI® as early as first relapse, the disease did not progress and no further treatment was required at 2.5 years (30 months

Description: Johnson & Johnson’s latest narrative has tilted more constructive, with fresh research nudging its fair value estimate higher from about $200.82 to $202.54 per share and reaffirming a roughly 6.96% discount rate that underscores a steady risk return profile. Analysts are increasingly crediting portfolio simplification and improving growth drivers for this modest fair value upgrade, suggesting the market may be slowly reassessing the stock’s long term earnings potential. Stay tuned to see how...

Description: Bristol-Myers Squibb Company (NYSE:BMY) is one of the stocks Jim Cramer commented on along with the recent macro rally. Cramer mentioned the stock during the episode, as he commented: “Then it might be a comeback to the drug stocks. Why? Well, remember, lots of people think the economy is stalled or in a tailspin. They’re […]

Description: Johnson & Johnson (NYSE:JNJ) announced today that new data from the investigational Cohort 4 of the Phase 2b SunRISe-1 study show treatment with gemcitabine intravesical system resulted in high one-year disease-free survival (DFS), progression-free survival (PFS), and overall survival (OS) rates in patients with Bacillus Calmette-Guérin (BCG)-unresponsive, high-risk, papillary-only non-muscle invasive bladder cancer (NMIBC).1 These data were featured as a late-breaking oral presentation at the S

Description: The urgency at banks to shed risk is visible all over credit markets. The cost of protecting Oracle Corp. debt against default using derivatives has risen to the highest since the Global Financial Crisis. Morgan Stanley has looked at using a significant risk transfer — a form of insurance against loan losses — to diffuse some of the risk tied to its tech company borrowers.

Description: Eli Lilly, Johnson & Johnson and Sanofi stay in focus as Big Pharma shows signs of recovery amid innovation, M&A and easing industry pressures.

Description: We came across a bullish thesis on Johnson & Johnson on Max Dividends’s Substack. In this article, we will summarize the bulls’ thesis on JNJ. Johnson & Johnson’s share was trading at $205.34 as of December 1st. JNJ’s trailing and forward P/E were 19.99 and 17.99 respectively according to Yahoo Finance. Johnson & Johnson (J&J) is a global […]

Description: The latest trading day saw Johnson & Johnson (JNJ) settling at $202.48, representing a -1.39% change from its previous close.

Description: When it comes to weathering market volatility, there is no easy answer, and what’s worse is that when investors, retail or otherwise, try to time the market, it usually ends in disaster. As a result, everyone is looking for a way to continue making money even when the market turns, and the easy answer to ... The Dividend Stocks That Keep Paying Even When Markets Stumble

Description: Genmab stock, Thursday's IBD Stock Of The Day, is just below an early entry in a cup case after announcing an $8 billion deal to buy Merus.

Description: MRK banks on Capvaxive, Winrevair and other new launches to counter Keytruda's looming 2028 LOE and record long-term growth.

Description: In the Large-Cap Pharmaceuticals industry, Lilly, J&J and Sanofi are worth retaining as the industry shows some recovery.

Description: ABBV rebounds after Humira's LOE as soaring Skyrizi and Rinvoq sales drive a powerful immunology comeback.

Description: The company’s chief medical officer discusses its trajectory with the blockbuster Brukinsa and its strong hematology pipeline.

Description: Johnson & Johnson (NYSE:JNJ) is included among the 15 Dividend Stocks that Outperform the S&P 500. Barclays lifted its price⁠ tar⁠g⁠et o⁠n Johnson & Johnson (NYSE:JNJ) to $197 from $176​ on December 2 while maintaining an E‌qua‌l Weight rating. Th‍e fi‍rm als​o refreshe⁠d its‌ estimates for the compan⁠y. Johnson & Johnson (NYSE:JNJ) continues t⁠o⁠ b‌enefit […]

Description: Neace Ventures’ acquisition of J&J Transportation Consultants and Thoroughbred Transportation may have flown under the radar when it was announced earlier this year, but it represents something much larger happening across the logistics industry. The Louisville-based private investment firm, traditionally known for its holdings in food, beverage, and consumer brands, has been steadily building out […] The post Acquisition through growth: The shift in logistics growth strategies appeared first on

Description: Bayer shares jump after the U.S. Solicitor General backs a Supreme Court review of its Roundup case, adding momentum to its strong 2025 run.

Description: The intraocular lens (IOL) market is projected to grow from US$ 4.46 billion in 2024 to US$ 7.16 billion by 2033, reflecting a CAGR of 5.41%. This booming industry is driven by the rising prevalence of cataracts and an aging population, alongside technological advancements in lens solutions such as multifocal and toric lenses. Major players like Novartis, Johnson & Johnson, and Alcon are spearheading innovations to enhance visual outcomes and meet global market demands, particularly in emerging

Description: Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Description: Johnson & Johnson (NYSE: JNJ) – Johnson & Johnson, a global leader in eye health, has partnered with Academy Award–nominated actress, producer, and entrepreneur, Naomi Watts, to change the conversation about vision. Together, they'll encourage simple, practical steps—such as routine eye checks and reframing eye care as part of holistic healthy aging, so that it becomes an easy and empowering part of daily self-care.

Description: Johnson & Johnson (NYSE:JNJ) ranks among the Best Low Volatility Investments in December 2025. On November 25, Guggenheim reaffirmed a Buy rating and $206 price target on healthcare giant Johnson & Johnson (NYSE:JNJ), citing favorable clinical trial findings for its multiple myeloma therapy. The firm noted preliminary data from the MajesTEC-3 trial, which combines Johnson […]

Description: The Global Medication Adherence Market presents opportunities driven by the rising prevalence of chronic diseases, an aging population, and healthcare tech advances, notably AI integration. Challenges include high medication costs. Key players like Johnson & Johnson and Omnicell are pivotal in this evolving landscape. Medication Adherence Market Medication Adherence Market Dublin, Dec. 02, 2025 (GLOBE NEWSWIRE) -- The "Medication Adherence Market - Global Industry Size, Share, Trends, Opportunit

Description: J&J gains EU approval for Imaavy, the first FcRn blocker for adults and adolescents with generalized myasthenia gravis.

Description: LifeStyles Healthcare ("LifeStyles"), a global intimate health and wellness platform, and Linden Capital Partners portfolio company, is pleased to announce the appointment of Peter Luther to its Board of Directors.

Description: The market has staged an impressive rebound, but is in for more volatility. The overarching up-and-down dynamic starts with the fact that sellers have been coming in near the market’s highs to knock stock prices lower because investors and traders know that the more artificial-intelligence spending happens today, the greater the likelihood that the spending will collapse tomorrow. The Cboe Volatility Index, which shows the magnitude of expected swings in stock prices, hit 18 early Monday, down from about 26 in mid November but above its low for the year of about 14.

Description: There are a number of valid reasons why many investors may be souring on the ability of equity markets to continue to rise at a 20%+ rate in the years to come. Indeed, it’s been an impressive run for investors in the stock market in recent years, with such outsized gains becoming the norm. That’s ... Time to Shore Up Your Personal Portfolio With These 3 Bullet-Proof Blue-Chip Stocks

Description: MBX Biosciences' sharp rally highlights how Zacks' stock recommendations outpaced broader market gains across multiple portfolios.

Description: National Veterinary Associates (NVA) today announced that Leslie Storms has been appointed President, Ethos Veterinary Health, effective immediately. She will also become an investor in the company. Ethos Veterinary Health is NVA's premier network of specialty and emergency care, comprised of over 140 hospitals and 1,500 team members across North America.

Description: Nipocalimab is the first FcRn blocker approved in both adult and adolescent gMG patients aged 12 and older who are anti-AChR or anti-MuSK antibody-positive In the pivotal Phase 3 Vivacity-MG3 and Phase 2/3 Vibrance-MG studies over 24 weeks, nipocalimab demonstrated rapid and substantial reduction in immunoglobulin G levels, one of the root causes of gMG gMG patients taking nipocalimab demonstrated up to 20 months of sustained disease control and symptom relief in the Vivacity-MG3 study and ongoi

Description: Leslie Storms started a new role on Monday as president of Ethos Veterinary Health.

Description: Bristol-Myers Squibb Company (NYSE:BMY) is included among the 15 Best Boring Dividend Stocks to Buy. Bayer repor⁠t​ed positive Phase‌ 3 result⁠s for its FXIa inhi‍bitor as​undexian, h‌itting key efficacy an‍d safety targets and dr‌awing renewed attention to the broader FXIa drug class. Morg​a⁠n Stanley noted this could increase interest i‌n s⁠imilar treatments from Bristol-Myers Squibb […]

Description: Kimberly-Clark Corporation (NASDAQ:KMB) is included among the 15 Best Boring Dividend Stocks to Buy. On⁠ November 13, Argus analy⁠st John St‌aszak upgraded Kimberly-Clark Corporation (NASDAQ:KMB) to a Buy ratin‍g​ from Hold and set a $120 price targ‌et, according to a report by The Fly. He pointed out that the stock has b‌een l‍agging lately, but […]

Description: Johnson & Johnson (NYSE:JNJ) is included among the 15 Best Boring Dividend Stocks to Buy. On Nov‌ember 18, Johnson & Johnson (NYSE:JNJ) revealed that it plans to acquire pr‌ivately held Halda​ Ther⁠apeutics f‍o‌r $3.05 billion i‍n c​ash,‍ a move intended to strengthen its pos‍ition in therapies focused on solid tumors and prostate cancer. The p‍urcha‌se […]

Description: If you buy companies with in-demand products and hold for the long term, you can end up with long-term winners.

Description: Patience will be rewarded for those who stick with these two healthcare stocks.

Description: Johnson & Johnson (NYSE:JNJ) is one of the stocks Jim Cramer discussed, along with the need for diversification. Cramer highlighted that he is fond of the stock, as he said: “You could own JNJ and Merck with their incredible franchises. You know what? I’m actually particularly fond of JNJ right now. They’re spinning off their […]

Description: JNJ's oncology sales surge on strong drug launches and pipeline momentum, raising the stakes for its ambitious $50B 2030 goal.

Description: Johnson & Johnson has outpaced the S&P 500 over the past year, and analysts remain optimistic about the healthcare stock's growth potential ahead.

Description: Wondering if Johnson & Johnson stock is a hidden gem or already fully priced? This article will break down everything you need to know about its current value. The share price recently moved up by 11.2% over the last month, contributing to a strong 44.1% year-to-date return and a 38.0% gain over the past year. These changes may indicate growing investor confidence or shifting risk perceptions. Recent headlines indicate that Johnson & Johnson is strengthening its market position with major...

Description: We recently published 10 Best Small-Cap Stocks With Huge Potential According to Reddit as Market Looks Beyond AI Trade. Halozyme Therapeutics, Inc. (NASDAQ:HALO) is among the best small-cap stocks to buy according to Redditors. Halozyme Therapeutics, Inc. (NASDAQ:HALO) is one of the best small-cap stocks with huge upside potential according to Redditors. The company is […]

Description: Dividends can help enrich your portfolio for years to come.

Description: These top dividend stocks could intrigue a wide range of investors.

Description: Bristol Myers wins EC approval to expand Breyanzi's label, adding MCL patients to its growing roster of European CAR-T indications.

Description: The layoffs affect Swiss manufacturing facilities. Elsewhere, the FDA pushed back an approval deadline and a mid-stage study showed Novo’s amycretin helps regulate blood sugar.

Description: Extending Medicare reimbursement for cardiac catheter ablation to settings outside the hospital is expected to boost procedure volumes and benefit Abbott, Boston Scientific, J&J and Medtronic.

Description: Ever wondered if Kenvue is a hidden value play or if its recent price is telling us something different? Today, we are unpacking whether the current share price is a bargain or a warning sign for investors. Kenvue’s stock price has caught some attention lately, climbing 4.9% over the last week and jumping 13.5% for the past month. This comes despite a drop of 20.0% year-to-date and 26.5% over the last year. In recent weeks, headlines have highlighted Kenvue’s continued integration efforts...

Description: Johnson & Johnson (JNJ) shares have edged higher over the past month, building on a steady run that has seen the stock advance 17% in the past 3 months. Investors are watching for what comes next as momentum builds. See our latest analysis for Johnson & Johnson. The share price momentum for Johnson & Johnson has been impressive, with steady gains this year suggesting renewed investor confidence as the company continues to navigate a shifting healthcare landscape. Over the past year, the total...

Description: Bristol Myers wins EC approval to expand Breyanzi's label, adding MCL patients to its growing roster of European CAR-T indications.

Description: J&J's 16.7% rise reflects stronger sales guidance, rapid pipeline advances and improving MedTech momentum amid a recovering sector.

Description: The trial proved so successful that Bayer plans to reach out to regulators in preparation for submitting the drug candidate for approval.

Description: As pharma’s U.S. facility investments top $370 billion over the next five years, there are a few things to keep in mind, according to construction experts.

Description: Johnson & Johnson (NYSE:JNJ) is a global healthcare company that develops, manufactures, and sells pharmaceutical products and medical devices. It is set to report its Q4 2025 earnings on Jan. 21. Wall Street analysts expect the company to post EPS of ...

Description: Financial foundation toward self-sustained long-term growth established with the closing with HealthCare Royalty (“HCRx”) of a non-dilutive royalty financing valued up to $71 millionProgress in the JNJ-1900 (NBTXR3) global development program announced including first data from a Phase 1 esophageal cancer study sponsored by The University of Texas MD Anderson Cancer Center (“MD Anderson”)Completed the NANORAY-312 sponsorship transfer to Johnson & Johnson in the majority of regionsAdvanced the Cu

Description: Bayer's asundexian hits key goals in the OCEANIC-STROKE study, showing reduced ischemic stroke risk without added major bleeding.

Description: CorpGov and IPO Edge are pleased to provide complete video coverage of the fifth annual Palm Beach CorpGov Forum held on Nov. 5-6, featuring keynote speaker Josh Frank, Partner and Co-Chief Investment Officer at Wall Street legend Nelson Peltz’s Trian Fund Management. Mr. Frank discussed Trian’s position for the last six years at Unilever PLC […] The post EXCLUSIVE: Sustainable Value Creation: Keynote Fireside with Trian Fund Management, 5th Palm Beach CorpGov Forum appeared first on CorpGov.

Description: The Hip Replacement industry is poised for substantial growth, projected to reach US$ 10.24 billion by 2033, up from US$ 6.92 billion in 2024, at a CAGR of 4.45% between 2025 and 2033. This expansion is driven by increased awareness of procedures such as hip arthroplasty, which helps alleviate discomfort and enhance mobility for those with severe joint disorders. Factors such as rising obesity, orthopedic issues, and demand for surgical treatments contribute to market growth. Key players driving

Description: It has grown wildly, and it could keep growing.

Description: RVL Pharmaceuticals, Inc and its affiliates (together, "RVL") today announced a series of senior leadership appointments to strengthen the organization and position the company for accelerated growth across its business, including its flagship product, Upneeq® (oxymetazoline hydrochloride ophthalmic solution), 0.1%.

Description: Kimberly-Clark Corporation (NASDAQ:KMB) is one of the stocks Jim Cramer recently offered insights on. Cramer discussed the company’s planned acquisition of Kenvue during the episode. He said: “Alright, this is one we’ve talked about a bunch, Kimberly-Clark’s bold, nearly $49 billion bid to buy Kenvue, which is the J&J’s old over-the-counter business that makes Tylenol, […]

Description: Kenvue Inc. (NYSE:KVUE) is one of the stocks on Jim Cramer’s radar recently. During the lightning round, a caller asked if long-term shareholders should be worried. Here’s what Mad Money’s host had to say in response: “Okay, it’s a really important question because I’ve been looking to buy Kimberly. I think the answer is no. […]

Description: Johnson & Johnson's stock narrative has seen a notable development, with the consensus analyst price target rising slightly from $199.56 to $200.82. This adjustment reflects renewed optimism driven by a combination of strong business execution, strategic initiatives such as the planned orthopedics spin-out, and confidence in the company's robust pipeline. Stay tuned to discover how you can monitor future updates to Johnson & Johnson's evolving outlook. Stay updated as the Fair Value for...

Description: Despite PIPE-307’s failure in RRMS, analysts still have hope for the candidate in major depressive disorder (MDD).

Description: A spate of promising news is helping to extend a post-earnings rally for the healthcare giant's shares.

Description: Lilly becomes the first pharmaceutical company to hit that threshold, joining a select club of mostly tech companies.

Description: LLY's expanding AI alliances highlight how pharma-tech partnerships are transforming healthcare and lifting key sector ETFs like XLV.

Description: The medical technology stock is in a consolidation pattern and testing a key level. The biotech had a beat-and-raise quarter.

Description: HOLX's GYN Surgical segment posts its strongest fiscal 2025 growth as MyoSure, Fluent and Gynesonics fuel a standout quarter.

Description: The global surgical stapling devices market, valued at $5.23 billion in 2023, is anticipated to grow to $8.32 billion by 2029, with a CAGR of approximately 8%. This growth is propelled by the rising demand for minimally invasive procedures and increased healthcare investments, especially in emerging nations. Market segmentation highlights the dominance of disposable and powered surgical stapling devices due to convenience and enhanced functionality. North America leads, driven by innovative tech

Description: BMY ends its Librexia ACS study after an interim review shows milvexian is unlikely to meet goals, while other late-stage studies continue.

Description: MIAMI, FL / ACCESS Newswire / November 20, 2025 /OMP, a global leader in supply chain planning solutions, brought together global supply chain executives, technology innovators, and strategic partners at the OMP REAL Conference 2025 in Miami. Held ...

Description: Clarity Eye Centre announced the arrival of Johnson & Johnson's next-generation SILK™ Laser Eye Technology, now available to patients in Hong Kong. The clinic is the first in the city to widely offer the ELITA™ Femtosecond Laser, the advanced system that powers SILK™ (Smooth Incision Lenticule Keratomileusis), ushering in a new era of precision and gentle laser vision correction for myopia, with or without astigmatism.[1]

Description: Health care stocks fell late Wednesday afternoon with the NYSE Health Care Index easing 0.1% and the

Description: Eli Lilly and J&J recently announced partnerships with AI chipmaker Nvidia, pointing to a broader trend of tie-ups to advance drug discovery and improve workflows.

Description: Johnson & Johnson had strong Q3 results and reported an important acquisition.

Description: MRK's Winrevair hits its phase II goal in patients with CpcPH tied to HFpEF, setting up phase III plans and a potential path to broader use. Stock up.

Description: Knee replacement surgery effectively addresses severe knee conditions like osteoarthritis, offering pain relief and improved mobility. The procedure sees high demand due to rising osteoarthritis among the aging population, especially as global lifespans increase. Although the surgery significantly enhances life quality, challenges such as high costs and lengthy recovery persist, affecting both patients and healthcare systems. The competitive market witnesses innovation from key players like Stry

Description: ABBV rebounds after its Q3 dip as strong immunology and neuroscience growth offset Humira erosion and aesthetics weakness.

Description: Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Description: Bayer wins EU approval for Lynkuet, expanding its pharma portfolio with a hormone-free treatment for moderate to severe vasomotor symptoms

Description: Intuitive Surgical's Ion platform represents robust growth potential with strong procedure growth. Clinical trial data demonstrate superiority in diagnostic yield.

Description: In November 2025, Johnson & Johnson announced several major product developments, including new FDA approvals for DARZALEX Faspro in high-risk smoldering multiple myeloma, CAPLYTA as an adjunctive treatment for major depressive disorder, and positive late-stage clinical results for TREMFYA in psoriatic arthritis. These achievements underline Johnson & Johnson's momentum in expanding its pharmaceutical portfolio with treatments targeting significant unmet medical needs across oncology,...

Description: J&J's $3.05B move for Halda adds targeted oral cancer therapies and expands its prostate cancer pipeline amid rising pharma M&A.

Description: ABBV's neuroscience drugs drive strong Q3 momentum, with rising Botox Therapeutic sales, migraine therapies and new PD treatments fueling growth.

Description: J&J this year lost its patent exclusivity for Stelara, its longtime top-selling drug that treats psoriasis and inflammatory bowel disease.

Description: The acquisition brings Halda's candidate HLD-0915, a clinical-stage treatment for prostate cancer, into J&J's oncology portfolio.

Description: Lilly shines for growth seekers while J&J offers steady, lower-risk stability as both pharma giants advance pipelines and post rising estimates.

Description: Deal adds new prostate cancer candidate and supports J&J's long-term oncology strategy.

Description: Johnson & Johnson said Monday it's putting up $3.05 billion to buy privately held cancer player Halda Therapeutics.

Description: The Dow Jones index fell on the stock market today. Lithium stocks rose on bullish commentary. Alphabet jumped on a Warren Buffett move but Peter Thiel dumped a key AI stock.

Description: Health care stocks were decreasing late Monday afternoon with the NYSE Health Care Index and the Hea

Description: Halda is testing a prostate cancer drug. J&J says that with the acquisition it will gain a platform for treating “diseases beyond oncology.”

Description: The Dow Jones Industrial Average was down, the Nasdaq Composite was higher, and the S&P 500 was roug

Description: (Corrected to add "billion" in headline.) Johnson & Johnson (JNJ) has agreed to buy Halda Therape

Description: Market Catalysts host Julie Hyman tracks several of the day's top trending stock tickers, including Johnson & Johnson's (JNJ) move to broaden its cancer research portfolio by acquiring Halda Therapeutics for $3 billion, Sinclair Broadcast Group (SBGI) taking a stake in broadcasting company E.W. Scripps (SSP), and bubble-wrap inventor Sealed Air (SEE) agreeing to go private in a deal with private equity firm CD&R. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts.

Description: Johnson & Johnson (JNJ) has agreed to buy Halda Therapeutics for $3.05 billion in cash as the health

Description: BMY shares drop after halting the Librexia ACS trial, though other milvexian studies continue with top-line data expected in 2026.

Description: Macy's climbs after a Zacks upgrade as multiple portfolios showcase strong gains across UNFI, Monster Beverage and other standout stocks.

Description: Johnson & Johnson has agreed to buy clinical-stage biotechnology company Halda Therapeutics for $3.05 billion in cash in a deal that bolsters the healthcare giant’s oncology pipeline.

Description: Halda to be acquired by Johnson & Johnson for $3.05 billion in cashHalda recently presented positive Phase 1/2 data for HLD-0915 in metastatic castration-resistant prostate cancer and continues rapid clinical developmentAdditional RIPTAC™ programs in development for major solid tumor types and other serious diseases NEW HAVEN, Conn., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Halda Therapeutics announced today that it has entered into a definitive agreement pursuant to which Johnson & Johnson will acquir

Description: Johnson & Johnson (NYSE: JNJ) today announced new data from the Phase 3b APEX study showing that TREMFYA® continued to reduce both signs and symptoms of active psoriatic arthritis (PsA) and inhibit progression of structural damage at 48 weeks.1 These data were presented at the Inflammatory Skin Disease Summit (ISDS) 2025.

Description: NEW BRUNSWICK, N.J., November 17, 2025--Johnson & Johnson (NYSE: JNJ) announced today that it has entered into a definitive agreement to acquire Halda Therapeutics OpCo, Inc. (Halda), a clinical-stage biotechnology company with a proprietary Regulated Induced Proximity TArgeting Chimera (RIPTAC™) platform to develop oral, targeted therapies for multiple types of solid tumors, including prostate cancer, for $3.05 billion in cash. The transaction is expected to close within the next few months, su

Description: Eli Lilly's surging GLP-1 momentum and Johnson & Johnson's diversified strength set up a compelling 2025 showdown for investors weighing growth vs. stability.

Description: The deal gives J&J access to a pipeline of drugs designed to “hold and kill” tumors, led by a prostate cancer medicine that’s shown promise in early-stage testing.

Description: Johnson & Johnson (NYSE:JNJ) is included among the 15 Best Passive Income Stocks to Buy Right Now. On November 12, Scotiabank’s Louise Chen began coverag‍e of ten large-cap biopharma companies and took a positiv‍e‍ st‌ance‌ on the sect‍or, n‌oting th⁠at‌ years of lagging performance compared with other‍ industrie‌s and majo‍r indices ma‍y offe⁠r in​vestors an appealing […]

Description: Shares of Bristol Myers Squibb slumped Friday after the company scrapped a study testing a treatment for acute coronary syndrome.

Description: Health care stocks fell late Friday afternoon, with the NYSE Health Care Index down 0.3% and the Hea

Description: US equity indexes were mixed ahead of Friday's close amid selective dip-buying in technology and inf

Description: US equity indexes were mixed in midday trading on Friday, with technology and energy leading the sec

Description: Pfizer's fair value estimate has inched upward recently, rising from $28.86 to $29.08 per share. The discount rate has climbed slightly as well. Analysts note this shift reflects a blend of enthusiasm for new pipeline additions alongside prudent awareness of industry headwinds. Stay tuned to discover how evolving market developments continue to shape Pfizer's investment outlook and what to watch going forward. Analyst Price Targets don't always capture the full story. Head over to our Company...

Description: Bristol said it had decided to stop one of its ongoing Phase 3 trials testing an experimental blood thinner called milvexian.

Description: Major U.S. equities indexes were mixed Friday afternoon, following a sharp decline Thursday fueled by a selloff of tech stocks.

Description: US equity indexes were mixed in midday trading on Friday, with technology and energy leading the sec

Description: Amgen Inc. (NASDAQ:AMGN) is one of the stocks Jim Cramer mentioned in his latest comments. Cramer highlighted the company’s breakthrough medicine, as he remarked: “We had Amgen on the show the other day, announcing a breakthrough in Repatha, its every other week injection squelches cholesterol to a level where it helps prevent heart attacks. Why […]

Description: A Texas judge will weigh Texas Attorney General Ken Paxton's bid to block Kenvue's (KVUE) November d

Description: Health care stocks were declining premarket Friday, with the Health Care Select Sector SPDR Fund (XL

Description: Pharma ETFs like IHE and PPH are rallying as strong Q3 earnings across major pharmaceutical companies lift sector sentiment.

Description: PRINCETON, N.J., November 14, 2025--Update on Phase 3 Librexia ACS Trial

Description: Amgen Inc. (NASDAQ:AMGN) is one of the stocks Jim Cramer recently put under a microscope. Cramer showed quite a bullish sentiment toward the company’s stock, as he remarked: “If you want to venture beyond what we call the CPG, consumer packaged goods, world, I think you’d do very well with owning J&J or Amgen… Amgen’s […]

Description: Johnson & Johnson (NYSE:JNJ) is one of the stocks Jim Cramer recently put under a microscope. Cramer said that “you’d do very well” owning the stock, as he stated: “If you want to venture beyond what we call the CPG, consumer packaged goods, world, I think you’d do very well with owning J&J or Amgen… […]

Description: We recently published Jim Cramer Discussed These 25 Stocks In An Important Show About AI Spending. Johnson & Johnson (NYSE:JNJ) is one of the stocks Jim Cramer recently discussed. Johnson & Johnson (NYSE:JNJ) is one of the biggest healthcare and pharmaceutical companies in the world. The firm recently spun off its orthopedic business, and Cramer […]

Description: Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Description: Nike upgraded, Dollar Tree downgraded: Wall Street's top analyst calls

Description: As National Alzheimer's Awareness Month spotlights new treatments, healthcare ETFs like XLV and VHT might gain fresh investor appeal.

Description: If you're a new investor looking for some long-term opportunities, don't overlook these top healthcare buys.

Description: These top dividend payers could enrich a long-term investor's portfolio.

Description: BeOne Medicines is Wednesday's IBD Stock Of The Day. The IBD 50 biotech is breaking out after a record-breaking quarter.

Description: Bank of America came up with 16 names that investors should consider buying. Renaissance Macro threw out a couple of sector ideas, too.

Description: Bayer's Q3 earnings surged on Crop Science strength, offsetting pricing and currency headwinds across divisions.

Description: Precision medicine and next-gen biologics are transforming patient care. Despite cost-related challenges, key players like AbbVie, Johnson & Johnson, and Bristol-Myers Squibb are leading innovations.Dublin, Nov. 12, 2025 (GLOBE NEWSWIRE) -- The "Psoriatic Arthritis Market - A Global and Regional Analysis: Focus on Drug Type and Region - Analysis and Forecast, 2025-2035" has been added to ResearchAndMarkets.com's offering. The growing prevalence of autoimmune diseases, particularly among individu

Description: ABBV's growth engine keeps humming as Skyrizi and Rinvoq together now power more than 40% of total revenues and drive new market share gains.

Description: These companies are demonstrating their ability to deal with significant business risks.

Description: He bought Nvidia at $101, rode the AI wave to solid gains, and then dumped everything. In a post on the Stocks subreddit, a 25-year-old investor said he sold his entire portfolio—including top performers like Nvidia (NASDAQ:NVDA), Broadcom (NASDAQ:AVGO), and Alphabet (NASDAQ:GOOG, GOOGL)) —because he's convinced the market is sitting on a ticking time bomb. "I have SOLD IT ALL because I fear that it might crash because of all the uncertainty and overvaluation," he wrote. Despite gaining around 1

Description: J&J's MedTech sales rose 5.6% in Q3, fueled by cardiovascular strength and strategic portfolio shifts toward high-growth markets.

Description: Wondering if Johnson & Johnson is a bargain or overpriced right now? You are not alone. Plenty of investors are questioning whether its shares offer value at today's levels. The stock has shown solid momentum lately, climbing 3.7% in the last week and 1.6% over the past month, with a striking 34.6% year-to-date run. Driving some of this share price action are developments such as the company's recent acquisition in the medtech space and expanded strategic partnerships, both of which have...

Description: A number of stocks jumped in the afternoon session after the market experienced a sharp sector rotation, as investors fled growth-oriented technology stocks and piled into value-oriented names amid growing valuation concerns. This divergence was stark: the tech-heavy Nasdaq struggled, losing 0.2%, while the Dow rallied. This shift away from tech was triggered by a series of negative catalysts in the AI sector. AI cloud provider CoreWeave slid on disappointing guidance, while chip darling Nvidia

Description: A number of stocks jumped in the afternoon session after the market experienced a sharp sector rotation, as investors fled growth-oriented technology stocks and piled into value-oriented names amid growing valuation concerns. This divergence was stark: the tech-heavy Nasdaq struggled, losing 0.2%, while the Dow rallied. This shift away from tech was triggered by a series of negative catalysts in the AI sector. AI cloud provider CoreWeave slid on disappointing guidance, while chip darling Nvidia

Description: A number of stocks jumped in the afternoon session after the market experienced a sharp sector rotation, as investors fled growth-oriented technology stocks and piled into value-oriented names amid growing valuation concerns.

Description: A number of stocks jumped in the afternoon session after the market experienced a sharp sector rotation, as investors fled growth-oriented technology stocks and piled into value-oriented names amid growing valuation concerns.

Description: A number of stocks jumped in the afternoon session after the market experienced a sharp sector rotation, as investors fled growth-oriented technology stocks and piled into value-oriented names amid growing valuation concerns.

Description: A number of stocks jumped in the afternoon session after the market experienced a sharp sector rotation, as investors fled growth-oriented technology stocks and piled into value-oriented names amid growing valuation concerns.

Description: A number of stocks jumped in the afternoon session after the market experienced a sharp sector rotation, as investors fled growth-oriented technology stocks and piled into value-oriented names amid growing valuation concerns.

Description: Johnson & Johnson (JNJ) just secured back-to-back FDA approvals for two therapies, representing a meaningful expansion in both its oncology and neuropsychiatry portfolios. These developments could open up additional opportunities for long-term growth. See our latest analysis for Johnson & Johnson. These approvals have come amid a stretch of strong momentum for Johnson & Johnson, with the stock delivering a robust 9.05% share price gain over the last quarter and an impressive 25.45% total...

Description: Market opportunities in the Pulmonary Arterial Hypertension (PAH) sector include increased demand for innovative therapies due to rising PAH prevalence and greater awareness, alongside enhanced diagnostic capabilities. The shift towards personalized medicine and digital health tools also offers avenues for optimizing treatment efficacy and patient management. Pulmonary Arterial Hypertension Market Pulmonary Arterial Hypertension Market Dublin, Nov. 11, 2025 (GLOBE NEWSWIRE) -- The "Pulmonary Art

Description: The average brokerage recommendation (ABR) for Johnson & Johnson (JNJ) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?

Description: President and CEO Joni Odum has driven plans to boost revenue at Firstline Brands to $50M within the next five years.

Description: Haleon plc (NYSE:HLN) is one of the stocks Jim Cramer recently discussed. Cramer highlighted the stock’s struggles, as he commented: “With Kimberly-Clark shelling out nearly $49 billion to buy Kenvue, which was originally J&J’s over-the-counter medicine business, I think it’s time to check in with Haleon, the former consumer business of GlaxoSmithKline and Pfizer… Oh, […]

Description: Bristol-Myers Squibb Company (NYSE:BMY) is one of the stocks Jim Cramer recently shared thoughts on. Cramer showed his disappointment in the company’s schizophrenia medicine sales, as he commented: “Look, I, my Charitable Trust owns Bristol, looks like a mistake because I, I believed in Cobenfy, which is a, a pretty good product, but it’s not […]

Description: In recent days, Recursion Pharmaceuticals announced a major leadership transition appointing Najat Khan, Ph.D., as CEO effective January 1, 2026, while also securing a milestone payment from Roche and Genentech for delivering a whole-genome microglial immune cell map. This leadership change brings an executive with significant AI-driven drug discovery experience at Johnson & Johnson, coinciding with cumulative partner milestone payments at the company surpassing US$500 million. We'll now...

Description: This approval marks a milestone for high-risk sMM patients, but analyst Biswajit Podder notes that there are caveats to its future success.

Description: These five Dividend Kings offer investors a solid source of passive income, and are among the safest picks in the group.

Description: Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Johnson & Johnson received U.S. Food and Drug Administration (FDA) approval of a new indication for DARZALEX Faspro® (daratumumab and hyaluronidase-fihj) co-formulated with ENHANZE®, as single agent treatment of adult patients with high-risk smoldering multiple myeloma (HR-SMM). DARZALEX Faspro® is the first and only approved treatment for HR-SMM, enabling earlier intervention before the disease progresses to active multi

Description: Johnson & Johnson (NYSE:JNJ) today announced the U.S. Food and Drug Administration (FDA) approved DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) as a single agent treatment for adult patients with high-risk smoldering multiple myeloma (HR-SMM).1 DARZALEX FASPRO® is the first and only approved treatment for HR-SMM, enabling earlier intervention before the disease progresses to active multiple myeloma.

Description: Johnson & Johnson's stock price target has seen a slight increase, with the Fair Value Estimate rising from $198.03 to $199.56 following recent analyst updates. This adjustment reflects the company's strong operational performance, a positive outlook on business portfolio changes, and encouraging signals from its innovative medicine segment. Stay tuned to discover how you can continue tracking the evolving narrative around Johnson & Johnson's shares as the story develops. Analyst Price...

Description: Caplyta’s MDD label extension marks the first approval since J&J acquired the drug in a $14.6bn buyout.

Description: Attorney General Ken Paxton filed a motion in a Texas District court on Wednesday to prevent Kenvue

Description: The company has paused some UK investment plans, citing declining government support for pharmaceutical innovation.

Description: The market is expanding due to rising cardiovascular disease prevalence, an aging population, and advancements in treatments like SGLT2 inhibitors. Integration of digital health solutions and personalized medicine are key trends reshaping the landscape, enhancing patient outcomes and quality of life.Dublin, Nov. 06, 2025 (GLOBE NEWSWIRE) -- The "Chronic Heart Failure Market - A Global and Regional Analysis: Analysis and Forecast, 2025-2035" has been added to ResearchAndMarkets.com's offering. Co

Description: AstraZeneca's (AZN, AZN.L, AZN.ST) Q3 revenues surpassed $15 billion thanks to soaring sales of cancer drugs. CEO Pascal Soriot told Market Sunrise host Ramzan Karmali that the drugmaker has big plans to expand in the US to win market share. The Anglo-Swedish firm faces fierce competition from the likes of Johnson & Johnson (JNJ), Merck (MRK) and Pfizer (PFE). For more live coverage of the markets, watch the full episode of Market Sunrise and visit Yahoo Finance.

Description: Johnson & Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Administration (FDA) approved CAPLYTA® (lumateperone) as an adjunctive therapy with antidepressants for the treatment of major depressive disorder (MDD) in adults. The approval – the first under J&J leadership following its acquisition of Intra-Cellular Therapies, Inc. – provides patients with a safe and effective new treatment option that can enable a path to remission. CAPLYTA® makes it easy to start and stay on treatmen

Description: Caplyta, which J&J got in its acquisition of Intra-Cellular Therapies, netted a clearance in major depressive disorder that’s key to achieving the $5 billion in annualized sales the company expects.

Description: INCHEON, Korea, November 06, 2025--Samsung Bioepis has signed a settlement and license agreement with Johnson & Johnson concerning the commercialization of PYZCHIVA®, in Europe.

Description: Zimmer Biomet, the maker of knee and hip replacements, missed on quarterly sales estimates and lowered the top end of its outlook for full-year organic revenue growth.

Description: Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Description: We recently published 11 Latest Stocks Jim Cramer Talked About. Kimberly-Clark Corporation (NASDAQ:KMB) is one of the stocks Jim Cramer recently discussed. Along with OpenAI’s Amazon deal, Kimberly-Clark Corporation (NASDAQ:KMB) also made headlines after it announced that it would acquire household and personal products company Kenvue for $48.7 billion. Cramer discussed Kimberly-Clark Corporation (NASDAQ:KMB)’s CEO […]

Description: HALO posts strong third-quarter results with earnings and revenues topping estimates and raises 2025 guidance on robust royalty growth.

Description: Kenvue is under the microscope from the Trump administration, though Kimberly-Clark sees a $32bn horizon.

Description: The global disposable medical device market is set to expand from USD 113.95 billion in 2025 to USD 144.85 billion by 2030, driven by a 4.9% CAGR. Factors such as heightened concern over hospital-acquired infections (HAIs), increased surgical procedures, and demand for cost-effective, single-use solutions propel growth. The drug delivery devices segment is leading in growth due to rising chronic disease cases and vaccine programs. The plastic-based segment is growing due to cost-effectiveness an

Description: The deal, expected to close in the second half of 2026, comes as Kenvue's Tylenol political fight is heating up.

Description: Combined company aims to become global health leader by 2026.

Description: In the past week, Johnson & Johnson unveiled a series of positive clinical updates and regulatory milestones for key pipeline candidates, including icotrokinra and nipocalimab, across multiple immunology and dermatology indications. The announcements featured favorable long-term efficacy and safety data, new head-to-head trials, and expanded FDA designations, indicating pipeline strength and broadening commercial opportunities. One key insight is the mounting preference among patients and...

Description: The proposed biosimilar to J&J’s Simponi was rejected by the FDA due to manufacturing concerns.

Description: PARIS, November 04, 2025--Tulyp Medical, a Paris-based startup developing a medical device for intelligent pressure-driven perfusion, emerged from stealth and announced it has submitted its 510(k) application to the U.S. Food and Drug Administration (FDA). The company’s debut follows positive results from its initial first-in-human study.

Description: Kimberly-Clark shares suffered their biggest one-day drop since the 1980s after the Huggies diapers maker agreed to buy Kenvue. Shares in the Tylenol maker leapt. At the close of trading: Kimberly-Clark's stock fell 15% to $102.

Description: Global Aesthetics Leader Brings Deep Industry Expertise and Proven Track Record Driving Growth Across Health, Beauty, and Consumer Sectors Philippe Schaison Phillipe Schaison, PharmaD, to has been appointed to serve on The BeautyHealth Company Board of Directors. LONG BEACH, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- The BeautyHealth Company (NASDAQ: SKIN), home to flagship brand Hydrafacial, today announced the appointment of global aesthetics leader, Philippe Schaison, PharmaD, to its Board of

Description: Kimberly-Clark is buying Tylenol maker Kenvue for nearly $50 billion. The cash-and-stock transaction, announced Monday, values Kenvue at an enterprise value of about $48.7 billion, including debt. Under the terms of the deal, Kenvue shareholders will receive $21.01 a share, based on Kenvue’s closing price of $14.37 on Friday.

Description: Kenvue stock has struggled this year, but an acquisition offer is giving investors hope leading up to this week's earnings report.

Description: The purchase of Kenvue by Kimberly-Clark announced Monday would mark the close of a short, rocky term of independence for the Tylenol maker, which was spun off from Johnson & Johnson in 2023. Kenvue shares have been under pressure since President Trump’s warning that acetaminophen—the active ingredient in Tylenol—is a potential cause of autism. Kenvue has called the claims baseless.

Description: Caroline Woods: Big brands and big money - Kimberly-Clark is buying Kenvue in a nearly $50 billion cash and stock deal. That would put Huggies, Kleenex, Band-Aid, Neutrogena and Tylenol all under one roof. It’s one of the biggest deals on Wall Street this year and a major move for Kimberly-Clark, ...

Description: <body><p>STORY: :: Kimberly-Clark</p><p>Kimberly-Clarke is betting big on the maker of Tylenol, announcing it will acquire parent company Kenvue for more than $40 billion... marking the largest buyout ever among the U.S. consumer goods industry.</p><p>The historic deal comes after U.S. President Donald Trump made remarks about the painkiller at the White House in September, citing unproven claims linking Tylenol use during pregnancy to autism in children.</p><p>:: September 22, 2025</p><p>UPSOUND US PRESIDENT DONALD TRUMP: “Don't take Tylenol. Don't take it. If you just can't, I mean, fight like hell not to take it."</p><p>Shares of Tylenol-parent Kenvue - which also owns Band-Aid and Neutrogena - soared as much as 19% after the deal's announcement, while buyer Kimberly-Clark's shares tumbled about 14%.</p><p>:: File</p><p>Kenvue, which was spun off from Johnson & Johnson in 2023, has struggled for months with weak demand.</p><p>The company fired its CEO in July and said it was undergoing a strategic review of its assets.</p><p>Investor concern over Monday's merger announcement may stem in part from Kenvue's potential legal exposure to private lawsuits alleging it hid Tylenol's supposed link to autism in children.</p><p>U.S. sales of Tylenol fell 11% between September 20 and October 4 after Trump's remarks, according to a BNP Paribas analyst note last month.</p><p>:: Kimberly-Clark</p><p>But the merger does give Kimberly-Clark access to Kenvue's vast portfolio of brands - which also include Aveeno and Neutrogena - with the combined company expected to bring in annual revenues of roughly $32 billion.</p><p>The deal is expected to close in the second half of 2026.</p></body>

Description: Merger brings Huggies, Kleenex, and Tylenol under one roof

Description: Kenvue, the company that makes Tylenol, is fighting on both the political and scientific fronts. The latest blow came from the U.S. Health Secretary, placing even more pressure on Kenvue stock, which has already lost 40% of its value in the last six months. Robert F. Kennedy Jr. recently made ...

Description: Kenvue's value isn't obvious -- but a merged Kenvue and Kimberly-Clark might be a buy.

Description: Kleenex maker’s deal for troubled Johnson & Johnson spinoff comes amid lawsuits and regulatory scrutiny

Description: The deal will create a new consumer health giant, bringing Kenvue under the wing of the maker of Kleenex tissues and Huggies diapers

Description: Kimberly-Clark is buying Tylenol maker Kenvue in a cash and stock deal worth about $48.7 billion, creating a massive consumer health goods company. Shareholders of Kimberly-Clark will own about 54% of the combined company. Kenvue shareholders will own about 46% in what is one of the largest corporate takeovers this year.

Description: -Dr. Mates served as the Chairman, Chief Executive Officer, and Co-founder of Intra-Cellular Therapies, a mental health company, from June 2002 until it was acquired by Johnson & Johnson in 2025-HAYWARD, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace” DNA-directed RNA interference (“ddRNAi”) platf

Description: The deal is valued at $48.7 billion.

Description: Growth is driven by a rising demand for minimally invasive solutions, advances in technology, and increased beauty consciousness. The aging population and a booming MedSpa culture also contribute to market expansion. However, challenges include high costs and regulatory barriers. Major players like Johnson & Johnson and Galderma are key contributors to this evolving sector. Japanese Non-Invasive Aesthetic Treatment Market Japanese Non-Invasive Aesthetic Treatment Market Dublin, Nov. 03, 2025 (GL

Description: Even though Kenvue's stock was already in a tailspin before the FDA warned pregnant woman that Tylenol posed a health risk, there are still some lingering impacts to consider.

Description: Opportunities in the U.S. multiple myeloma market include leveraging cutting-edge therapies like targeted treatments and immunotherapies, capitalizing on aging demographics, increasing disease awareness, and investing in oncology research. Expansion in combination treatments also offers significant potential. U.S. Multiple Myeloma Market U.S. Multiple Myeloma Market Dublin, Nov. 03, 2025 (GLOBE NEWSWIRE) -- The "United States Multiple Myeloma Market Size, Insights, Analysis, Growth Potential and

Description: Johnson & Johnson has delivered a standout performance in 2025, outperforming both the broader market and the healthcare sector. Analysts continue to be fairly bullish on the stock’s trajectory.

Description: The global sun care products market is projected to grow at a CAGR of 4.77% between 2024 and 2030, driven by heightened skin health awareness and influencer marketing. Major players like Beiersdorf AG's NIVEA and Johnson & Johnson's Neutrogena are innovating, with products such as NIVEA's bespoke sun protection and Neutrogena's tie-up with John Cena for Ultra Sheer Mineral Sunscreen. North America leads the market, with over 35% share. The sun protection segment holds the largest share, while cr

Description: ABBV tops Q3 earnings and revenue estimates, driven by Rinvoq and Skyrizi gains, and lifts its 2025 EPS outlook.

Description: Black Diamond Therapeutics gears up for Q3 results as investors eye key silevertinib data and additional development plans.

Description: LYON, France, October 31, 2025--Regulatory News: POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic disorders, today announces the appointment of Yves Decadt as a member of its Board of Directors.

Description: Here are four options for supplementing your retirement.

Description: AbbVie stock dropped Friday after the biopharmaceutical company reported mixed results across its drug portfolios in the third quarter. Shares declined 4.7% to $217.50, putting AbbVie on pace for its lowest same-day percentage decrease since May 14, according to Dow Jones Market Data. Pharma peers traded mixed: Johnson & Johnson fell slightly while Pfizer gained 0.7%.

Description: Broadcom, Johnson & Johnson, and Palantir headline Zacks' latest analyst picks, with AI growth, pharma innovation, and defense tech momentum driving their outlooks.

Description: Broadcom's AI surge, J&J's resilient growth, and Palantir's defense-driven momentum headline today's top analyst reports.

Description: Dublin, Oct. 30, 2025 (GLOBE NEWSWIRE) -- The "Bladder Cancer Market - A Global and Regional Analysis: Analysis and Forecast, 2025-2035" has been added to ResearchAndMarkets.com's offering.The market's growth is primarily driven by the rising incidence of bladder cancer, advancements in diagnostic technologies, and the growing availability of innovative treatments such as immunotherapy and targeted therapies for bladder cancer management.Market Lifecycle StageThe market is currently in the expan

Description: Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Description: Bristol Myers Squibb hiked its full-year guidance on the back of a strong third quarter underlined by demand for drugs within its growth portfolio. The pharmaceutical giant raised its full-year revenue guidance to a range of $47.5 billion to $48 billion from a previous forecast of $46.5 billion to $47.5 billion. Bristol Myers now sees adjusted earnings between $6.40 and $6.60 a share, versus a previous range of $6.35 to $6.65 a share.

Description: RAHWAY, N.J., October 30, 2025--Merck & Co., Inc., Rahway, N.J., USA Announces Third-Quarter 2025 Financial Results

Description: On October 10, 2025, Ulta Beauty's Board of Directors appointed Christopher DelOrefice as Chief Financial Officer, effective December 5, 2025, following an extensive leadership career at Becton Dickinson & Company and Johnson & Johnson. The appointment comes as Ulta Beauty prepares for its third-quarter results amidst analyst expectations for a double-digit earnings drop and heightened margin pressures this year. We'll explore how investor focus on Ulta Beauty's upcoming earnings amid margin...

Description: GSK's Q3 earnings and revenue beat expectations, powered by HIV and oncology growth, prompting the company to lift its 2025 outlook.

Description: Johnson & Johnson (NYSE: JNJ) today announced plans to initiate the first head-to-head study comparing FcRn blockers for patients with generalized myasthenia gravis (gMG), which aims to affirm IMAAVY™ (nipocalimab-aahu) as the FcRn blocker of choice for appropriate gMG patients. The EPIC study design and Vibrance-MG Phase 2/3 long-term extension (LTE) data are among 38 abstracts the Company will present at the 2025 Myasthenia Gravis Foundation of America (MGFA) Scientific Session and the America

Description: Johnson & Johnson (NYSE:JNJ) is included among the Best Dividend Stocks for the Best Retirement Portfolio. On October 22, Free⁠dom Capital Mark‍ets has lowered i⁠ts‍ rating on Johnson & Johnson (NYSE:JNJ) from B‍uy to Hold, even as it raised the stock’s price tar⁠get fro‌m $180 to $19​0 f⁠oll​owing a solid third-qua⁠rte​r⁠ perform⁠ance. The healt‌hcare company […]

Description: Levin Papantonio legal team Levin Papantonio attorneys Cameron Stephenson, Chris Tisi, and Sara Papantonio FORT LAUDERDALE, Fla., Oct. 28, 2025 (GLOBE NEWSWIRE) -- A jury today awarded $20 million to the family of Dr. Alberto A. Casaretto, finding that Johnson & Johnson’s talc-based products caused his fatal mesothelioma. The lawsuit, brought by his son, Alberto Casaretto Jr., alleged that the company’s talc was contaminated with asbestos and that Johnson & Johnson failed to warn consumers. The

Description: Trying to figure out whether to buy, sell, or hold Johnson & Johnson? You are not alone. The stock price has been on a bit of a rollercoaster lately, closing most recently at $190.3. After a dip of 1.8% this past week, J&J is still up an impressive 5.9% over the last month, 32.1% year to date, and 21.6% in the past year. That kind of track record definitely attracts attention from investors searching for stable growth, but the real question is whether the current price makes sense compared to...

Description: The suit alleges that Kenvue hid autism risks of its popular pain reliever despite doctors saying it is safe to take during pregnancy.

Description: Texas joined the Trump administration in claiming Tylenol causes autism. Shares of Kenvue fell 3.2% Tuesday to $14.60 after Texas Attorney General Ken Paxton filed a suit alleging that the maker of Tylenol engaged in deceptive advertising that said the over-the-counter drug was safe to use while pregnant. The suit also named Johnson & Johnson which spun off Kenvue in 2023.

Description: Halozyme Therapeutics, Inc. (NASDAQ:HALO) is one of the most profitable biotech stocks to buy. H.C. Wainwright analyst Mitchell Kapoor maintained a Buy rating on Halozyme Therapeutics, Inc. (NASDAQ:HALO) on October 21, keeping the associated price target the same at $90. The analyst supported the optimistic rating with the company’s growth potential and the stability of […]

Description: Market Catalysts host Julie Hyman tracks several of the day's top trending stock tickers, including the state of Texas suing Johnson & Johnson (JNJ) and Kenvue (KVUE) over allegations that the companies hid the connections between Tylenol and Autism for pregnant women, D.R. Horton (DHI) topping quarterly home orders estimates, and Trump Media & Technology Group (DJT, DJTWW) offering predictions market features on Truth Social. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts.

Description: Since the turn of the century, the Dogs of the Dow have significantly outperformed the overall market. These five are perfect plays for a slowing economy.

Description: (Update with Kenvue's and Johnson & Johnson's responses to requests for comment from MT Newswires in

Description: They are about as safe as dividends can get.

Description: Intuitive Surgical's Q3 results impress, with da Vinci 5 adoption driving 23% revenue growth, though sustaining this rapid momentum may pose new challenges ahead.

Description: ABBV's Q3 results are likely to hinge on Skyrizi and Rinvoq growth, as Humira erosion and hefty IPR&D charges are expected to pressure near-term earnings.

Description: HALO gears up for third-quarter earnings with strong royalty growth and a new acquisition poised to shape its 2025 outlook.

Description: As earnings season accelerates, pharma heavyweights LLY, MRK, ABBV, BMY and GILD prepare to reveal their Q3 results amid a strong sector start.

Description: One growth stock, one high-yield stock, and one Dividend King -- you should find something you like here as October draws to a close.

Description: Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Description: J&J's diversified growth, strong pipeline, and robust balance sheet position it as a steadier long-term pick over Merck's Keytruda-dependent outlook.

Description: Protagonist Therapeutics (PTGX) said Monday that new data from two clinical studies of its investiga

Description: The company announced a formal plan to explore strategic alternatives for the segment, which has resulted in the spin-off.

Description: Johnson & Johnson (NYSE: JNJ) today announced findings from the U.S. dataset from the global ENCOMPASS study evaluating patient and healthcare provider (HCP) perspectives on barriers and unmet needs in psoriasis care. The results, presented at the 2025 Fall Clinical Dermatology Conference, reveal significant unmet needs and a strong preference for oral treatment options that achieve treatment goals with high efficacy and favorable safety.

Description: Johnson & Johnson (NYSE: JNJ) today announced Week 28 results from the Phase 2b ANTHEM-UC study of icotrokinra, a first-in-class investigational targeted oral peptide that precisely blocks the IL-23 receptor, in adults with moderately to severely active ulcerative colitis (UC). These results underscore the potential of icotrokinra to deliver a combination of therapeutic benefit and a favorable safety profile with once-daily oral dosing and will be featured among Johnson & Johnson's 23 accepted a

Description: Johnson & Johnson (NYSE: JNJ) today announced new 96-week data from the long-term extensions (LTE) of the Phase 3 GRAVITI, GALAXI 2 and GALAXI 3 studies, which show the durability of TREMFYA® (guselkumab) in adults with moderately to severely active Crohn's disease (CD) at two years.1 These findings are among 23 Johnson & Johnson abstracts being presented at the 2025 American College of Gastroenterology Annual Scientific Meeting (ACG).

Description: Investing.com -- Shares of Avidity Biosciences (NASDAQ:RNA) jumped more than 42% in premarket trading on Monday, while Dyne Therapeutics (NASDAQ:DYN) climbed over 20%, after Novartis announced an agreement to buy Avidity for about $12 billion in cash.

Description: If you are looking for high yields in the healthcare sector, here are three choices. Make sure you understand the risks before you buy them.

Description: Dividend investing offers a reliable path to passive income and long-term wealth building, especially when stock prices stagnate or decline. Regular payouts provide cash flow regardless of market direction, and reinvesting dividends historically drives much of total return. High-yield stocks, however, carry risks. Yields above 5% often signal underlying issues—declining earnings, high debt, or sector-specific ... 3 Dividend Stocks With Yields Over 5%. Should You Buy?

Description: Looking at high-yield healthcare stocks? These three stand out (but one has a slight skew to its story).

Description: Johnson & Johnson (JNJ) shares have edged mostly sideways over the past week, finishing at $190.40 in the latest session. Investors are weighing the company’s recent performance as revenue and net income both show modest annual growth. See our latest analysis for Johnson & Johnson. Johnson & Johnson’s share price has rallied impressively in 2024, notching a 32.2% year-to-date gain that reflects renewed optimism after a period of volatility. Despite a minor pullback in the past week, momentum...

Description: Johnson & Johnson (NYSE: JNJ) today announced findings from the Phase 2 DAHLIAS study published in The Lancet showing that nipocalimab, an investigational FcRn treatment for Sjögren's disease (SjD), significantly decreased disease activity and severity in patients with moderate-to-severe disease.1

Description: GSK stock crumbled Friday after the FDA granted its blood cancer treatment, Blenrep, a narrower-than-expected approval.

Description: Hopes of a U.S.-China trade truce are lifting sentiment for healthcare ETFs like XLV, IYH, and VHT, which could gain from easing tariffs and lower costs.

Description: MRK expects new products like Capvaxive, Winrevair, and the Animal Health business to support its top-line growth in the third quarter.

Description: Johnson & Johnson (NYSE: JNJ) today announced new long-term 52-week data from the Phase 3 ICONIC-TOTAL studya evaluating icotrokinra, a first-in-class investigational targeted oral peptide that precisely blocks the IL-23 receptor, in adults and pediatric patients 12 years of age and older (adolescents) with plaque psoriasis (PsO) affecting high-impact sites.

Description: PARIS and CAMBRIDGE, Mass., Oct. 24, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced updates to the JNJ-1900 (NBTXR3) clinical development program. Nanobiotix has completed the transfer of NANORAY-312 sponsorship, initiated in 3Q2024, in the majority of regions along with the tr

Description: Halozyme boosts its 2025 revenue outlook on surging royalties from Darzalex SC, Phesgo and Vyvgart Hytrulo, though partner reliance persists.

Description: MINNETONKA, Minn., October 23, 2025--AngioInsight, a leader in AI-powered cardiovascular diagnostics, today announced the appointment of Shlomi Nachman, former Worldwide Chairman of Johnson & Johnson’s Cardiovascular and Specialty Solutions (CSS), to its Board of Directors. AngioInsight is further announcing initiation of its Series A round of $25M, following the successful closing of its oversubscribed seed funding round. The investment will support the ongoing development of AngioAI+™, the com

Description: The GCC catheter market is projected to grow from USD 579.83 million in 2024 to USD 1.28 billion by 2033, with a CAGR of 9.21% from 2025 to 2033. This growth is driven by an increase in chronic diseases, surgical procedures, and advanced healthcare infrastructure across GCC countries. The demand for minimally invasive treatments and the aging population further bolster market expansion. Key sectors such as cardiovascular, microcatheters, and intermittent catheters are witnessing significant grow

Description: Johnson & Johnson stock has moved back into focus as analysts raise their consensus price target from $185.13 to $198.03. This reflects greater confidence following positive company developments. The upgraded target follows robust quarterly results and optimistic revised guidance, suggesting renewed momentum for the healthcare giant. Stay tuned to discover how you can follow these evolving perspectives and stay ahead of shifts in Johnson & Johnson’s investment narrative. What Wall Street Has...

Description: The former consumer health unit of Johnson & Johnson remains mired in troubles surrounding Tylenol.

Description: Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Description: Industry giants, including AstraZeneca, Johnson & Johnson, General Mills, and Kraft Heinz, to present real-world case studies in Miami MIAMI, FL / ACCESS Newswire / October 22, 2025 /OMP, a global leader in supply chain planning solutions, announced ...

Description: RA'ANANA, Israel, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira," “Inspira Technologies,” or the “Company”), a pioneer in innovative life-support and diagnostic technologies, today announced two key leadership appointments that reinforce its global commercialization and governance – the appointment of Mr. Mike Hershkovitz as Vice President of Global Sales of the Company and the appointment of Ms. Sivan Matza as a member of the board of directors

Description: Joining other honorees such as Adobe, IBM, Johnson & Johnson, and many others. NORTHAMPTON, MA / ACCESS Newswire / October 21, 2025 /Fast Company announced its seventh annual Best Workplaces for Innovators list, recognizing businesses that foster ...

Description: J&J projects faster 2026 growth in Innovative Medicine and MedTech, topping consensus estimates on both revenues and EPS.

Description: RA'ANANA, Israel, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira," “Inspira Technologies,” or the “Company”), a pioneer in innovative life-support and diagnostic technologies, today announced two key leadership appointments that reinforce its global commercialization and governance – the appointment of Mr. Mike Hershkovitz as Vice President of Global Sales of the Company and the appointment of Ms. Sivan Matza as a member of the board of directors

Description: Amazon has grown since it launched as an online bookstore in 1995 to become the dominant player in web hosting 30 years later. Amazon Web Services (AWS) was launched in 2006, and over the last decade, it has become the largest cloud computing provider in the world. AWS generated $107.6 billion in ...

Description: Kenvue Faces a Defining Moment: Leadership Shakeup and Strategic Review Signal Pressure for Change

Description: These three stocks have elevated yields and attractive dividend histories.

Description: Johnson & Johnson (JNJ) said Sunday that its subcutaneous formulation of amivantamab showed an overa

Description: These companies pay durable and steadily rising dividends.

Description: Johnson & Johnson (NYSE:JNJ) today announced promising new results from the Phase 1b/2 OrigAMI-4 study evaluating the efficacy and safety of subcutaneous (SC) amivantamab monotherapy in patients with human papillomavirus (HPV)-unrelated, recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) after disease progression on a checkpoint inhibitor and platinum-based chemotherapy. The study used the new subcutaneous formulation of amivantamab, which can be delivered in a five-minute

Description: The Standard & Poor's 500 index rose 1.7% this week as earnings season kicked off on a largely posit

Description: If the combination were to be approved, Tecvayli would expand out from its traditional role in fourth line treatment and beyond.

Description: JNJ's strong Q3 results, upbeat sales outlook and expanding drug pipeline highlight resilience despite Stelara LOE.

Description: BOSTON, October 17, 2025--Diorasis Therapeutics Welcomes Dr. Dimitri Azar to Its Board of Directors

Description: Combo beats investigator choice in relapsed setting

Description: Third quarter earnings season is just beginning, and analysts expect S&P 500 companies grew their profits by 8% during the quarter.

Description: The funding tranche follows HistoSonics’ $2.25bn acquisition by an investor consortium in August.

Description: Chris Lialios will continue as interim CFO until DelOrefice assumes the position in December 2025

Description: The company raised money from Bezos Expeditions, Thiel Bio and other investors to fund the commercial and clinical expansion of its technology.